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 Tuberculosis (TB) remains a critical threat to global human health. In 2016, 
1.7 million people died from the disease. Rifampin (RMP) remains a key component of 
the front-line treatment for TB, though resistance has presented challenges for its 
efficacy. Resistance to RMP (RMPR) primarily occurs through point mutations of its target, 
RNA polymerase, within the rifamycin resistance determining region (RRDR) in the β-
subunit. Three mutations constitute the bulk of RMPR, βD435V, βH445Y, and βS450L, 
with the latter being most prevalent in clinically resistant isolates. The molecular 
mechanisms which yield the observed distribution of RMPR mutations in MTB have been 
speculated upon; however, detailed in vitro studies of Mycobacterium tuberculosis (MTB) 
RNAP to elucidate those mechanisms have been lacking. This has likely been due, in 
part, to difficulty in acquiring pure MTB RNAP. To surmount this, an optimized 
methodology for the expression and purification of highly pure and active MTB RNAP is 
described. Co-expression of multiple vectors harboring all subunits of the RNAP 
holoenzyme allows for in vivo assembly of the holo RNAP complex. An optimized 
purification method was developed to acquire stoichiometric holo RNAP with high activity.
xii 
 
In vivo fitness defects have been observed in RMPR mutants of MTB RNAP. These 
defects have been found to be ameliorated by the presence of secondary mutations in 
double-psi β-barrel (DPBB) of the RNAP β’-subunit. To identify factors contributing to this 
fitness defect, several in vitro transcription assays were utilized to probe initiation, 
elongation, termination and RNA primer hydrolysis with the wild-type and RMPR RNAPs. 
Secondary, compensatory mutations are predominantly associated with the βS450L 
mutant, therefore this mutant was also studied in the presence of secondary mutations. 
We found that the RMPR mutants exhibit significantly poorer termination efficiency relative 
to wild-type, an important factor for proper gene expression. This may contribute to the 
relative prevalence of the RMPR mutants observed in MTB clinical isolates. We also found 
that several mechanistic aspects of transcription of the RifR mutant RNAPs are impacted 
relative to wild-type, particularly the stability of the open-promoter complex and elongation 
rate. For the βS450L mutant, these defects are mitigated in the presence of secondary 
mutations in the DPBB of the β’-subunit, making the intrinsic properties of this mutant 
similar to those of the wild-type. These data provide insight into the cost of antibiotic 
resistance to the fitness of the organism and a mechanistic basis for how MTB alleviates 
fitness defects associated with drug resistance. 
Drug resistant TB has become pervasive in large part due to a lack of novel 
therapeutics which act by new mechanisms of action. CarD is a global transcription 
regulator which acts by stabilizing the open-promoter complex of MTB RNAP and has 
been shown to be required for MTB viability. This suggests that CarD may be an effective 
and novel target for therapeutic discovery for the treatment of tuberculosis. A 
fluorescence polarization assay which monitors the association of MTB RNAP, native 
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rRNA promoter DNA and Bodipy-CarD has been developed, optimized and validated. A 
high throughput screen has been conducted to identify and characterize small molecule 
inhibitors which block the CarD•RNAP•DNA interaction. Several preliminary hits have 
been identified from this screen and initial secondary characterizations have been 
performed. This project will be the foundation for further investigation of CarD’s potential 






The discovery of antibiotics revolutionized the treatment of many common 
illnesses and infections which were almost certainly a death sentence previously. The 
mid 1900’s saw the discovery of several novel antibiotic classes and is known as the 
“golden era” for antibiotics.1 This “golden era” was short-lived, by the mid-1980’s rising 
levels of resistance to established treatments and a void due to the lack of new antibiotics 
in the pipeline has led to a new health crisis.2 Clinical resistance has been observed in all 
of the roughly dozen classes of antibiotics in use today. Most antibiotic resistance is the 
result of pervasive misuse of antibiotics in many sectors, from personal medicine to 
farming and agriculture.2 Resistance to antibiotics occurs by several mechanisms 
including antibiotic efflux, enzymatic modification of the drug or the drug target.3 Every 
year in the United States alone, 2 million people are infected with an antibiotic resistant 
pathogen and 23,000 deaths are attributed to antibiotic resistance.4 Identification of new 
treatments has been tenuous, and with the withdrawal of many pharmaceutical 
companies from infectious disease therapeutics research, discovery of new antibiotics is 
lacking. To compound the issue, one in five new drug candidates which reach Phase I 
clinical trials ultimately fail.5
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Tuberculosis and Mycobacterium tuberculosis 
Tuberculosis (TB) has plagued mankind for thousands of years and remains a 
major global health threat to this day. TB is the leading cause of death from infectious 
disease and ninth leading cause of mortality worldwide, with 1.7 million deaths attributed 
to the disease in 2016 (including deaths of 400,000 individuals co-infected with 
HIV/AIDS).6  The cause of TB is the pathogen Mycobacterium tuberculosis (MTB). An 
estimated 2 billion people or one-third of the global population are infected with MTB and 
in 2016 there were 10.4 million new cases of the disease.6 
A vast majority of the 2 billion people infected with MTB are asymptomatic; they 
carry the pathogen in a latent state.6 This latent tuberculosis infection (LTBI) occurs in 
90% of TB cases. Roughly 5% of TB cases result in active infection in the initial 18 months 
post exposure, after which people with LTBI have a 5% risk of reactivation during their 
lifetime.7-8 People with a compromised immune system, such as those co-infected with 
HIV/AIDs, have an increased risk of reactivation. Additionally, individuals with diabetes 
and those who consume alcohol or smoke are more likely to contract TB.6 For individuals 
with LTBI the use of either the tuberculin skin test or interferon gamma (IFN-γ) release 
assays, which indicate the presence of MTB antigens is used for diagnosis.6, 9 Four 
diagnostic methods are utilized for confirming the presence of active TB: X-ray, rapid 
molecular tests (Xpert MTB/RIF Assay), sputum smear microscopy, and other culture 
based methods. Rapid molecular tests (RMT) such as the Xpert MTB/RIF assay is the 
preferred diagnostic tool by the World Health Organization (WHO) as it can detect the 
presence of MTB as well as resistance to rifampin (the first-in-line treatment for TB) within 
a few hours.6 Although RMT is the preferred diagnostic method, culture-based methods 
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remain a requisite tool for monitoring disease progression and development of secondary 
resistance 
. 
Figure I-1: Tuberculosis health facts. A) Map of estimated global TB incidence rate for 
2016. B) Graphical representation of TB incidence with all TB cases (green), 
notification of new and relapse cases (black), and HIV-positive TB cases. C) 





M. tuberculosis pathogenesis 
MTB is communicable disease, which spreads when aerosolized pathogen is 
inhaled. Inhaled bacteria deposit in the distal alveoli and are internalized by macrophages 
and other phagocytic cells. Uptake of MTB into phagocytic cells is mediated by several 
cellular receptors including C-type lectin, scavenger receptors, and complement 
receptors.10 It is currently thought that route of pathogen entry into cells by different 
receptors plays a critical role in bacterial pathogenesis.11-12 
Even though MTB has been shown to colonize many cell types, a majority of 
research has focused on macrophages. Interestingly transcriptome data of MTB 
occupying different cell types varies possibly indicating multiple routes of pathogenesis.11 
Once the bacteria are phagocytized by the macrophage, MTB prevents maturation of the 
phagosome, avoiding formation of a degradative environment within the compartment.13-
15 There is growing evidence that MTB can replicate and persist in the cytosol.16 This 
escape from the phagosome compartment into the cytosol is thought to be mediated by 
Esx-1, a type VII secretion system (TSSS), which weakens the membrane of the 
phagosome.17 Autophagy, the endogenous mechanism to degrade cellular components 
and debris, is activated by IFN-γ and vitamin D, plays a role in the cellular recognition and 
targeting of MTB for clearance.18-19 Intracellular survival of MTB in macrophages is 
required for persistence of MTB. Activation of macrophages occurs from many stimuli 
including IFN-γ, vitamin D, and tumor necrosis factor with the former being produced by 
T lymphocytes.18, 20 Cell to cell spread of MTB is thought to occur by necrotic release of 
bacilli into the extracellular matrix. 
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Persister bacteria are isolated by the immune response within hardened structures 
called granulomas. Granulomas are composed of macrophages, lymphocytes and other 
immune cells and function to isolate MTB from nutrients, oxygen, and induce oxidative 
stress to produce a bactericidal environment.21 There are several granuloma subtypes 
including: caseous, non-necrotizing, neutrophil-rich, mineralized, and completely fibrotic 
or cavitary.22 It is this heterogeneity which produces individual and isolated 
microenvironments which dictate bacteria pathology. Lesions which compromise 
granuloma structure can release the bacteria, leading to dissemination and reactivation 
of TB infection. 
In order to survive within granulomas, MTB must enter a low metabolic state 
leading to a LTBI.23 Part of this transition is mediated by the stringent response.24 The 
stringent response is initiated by a drastic change in environmental conditions, mainly 
amino acid starvation; however, other cues have been shown to elicit the same 
response.24 The stringent response reprograms gene expression the bacteria adjust to 
its new environment. Part of this differential expression, at least in E. coli, is the direct 
modulation of RNA polymerase resulting in the reduction of rRNA and tRNA 
transcription.25 Other changes in transcription include an increase in gene expression 
associated with amino acid transport and biosynthesis. Guanosine 5’-diphosphate-
3’diphosphate (ppGpp) is a key effector molecule that mediates this reprogramming in 






Treatments for tuberculosis and Drug Resistance 
Tuberculosis has been pervasive for several millennia, having been recorded in 
many ancient geographically diverse cultures including the Egyptians, Peruvians, 
Chinese and Greek. Early recommendations for treatment of TB included fresh air, milk, 
and maritime travel by Greek physicians.26 In the late 1800’s Nobel laureate Herman 
Heinrich Robert Koch derived an extract from live MTB which he referred to tuberculin. 
He injected himself with the substance and it was later used to treat cattle by Danish 
veterinarians.27 What Koch did not know at the time was that he had not found a cure for 
TB but had rather discovered the MTB antigens which are still used to this day for the 
diagnosis of MTB infections. Later methodologies for the treatment of TB were mostly 
geared toward isolation of the patients in sanitoriums, preventing the spread of the 
disease. 
In the early 1900’s Albert Calmette and Camille Guérin began pioneering the first 
attempt at a vaccine for TB. Their work lead to the discovery of the BCG (Bacille Calmette-
Guérin) vaccine in 1921.28 This vaccine was used heavily after World War II by the World 
Health Organization (WHO) in an effort to eliminate the high prevalence of TB across the 
European continent and is widely accepted as one of the first major campaigns of mass 
vaccination.29 Over 14 million people were inoculated with the BCG vaccine. Though this 
vaccine was heavily used during the mid-20th century, the WHO now discourages its use 
with the exception of those predisposed to exposure and infants, because of a lack of 
uniform efficacy as well as confounding tuberculin skin testing.6, 30 
Treatment of TB was revolutionized by the advent of chemotherapies in the mid 
1900’s. The discovery and use of para-amino salicylic acid and thiosemicarbazone 
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represented the first chemotherapies used to treat TB infection and streptomycin was the 
first to show bactericidal effects on MTB.31 Major strides in curbing mass TB infection 
prevalence were not achieved until the discovery of isoniazid in 1952 and rifamycins in 
1957.32-33 These two therapies radically changed the treatment of TB infections and are 
currently the mainstay of first line TB treatment. 
Current recommendations for the treatment of TB involve a regime of multiple 
antibiotics. For new TB infections the treatment regime includes 2 months of rifampin, 
isoniazid, pyrazinamide, and ethambutol in a period known as the induction phase (see 
Table I-1).6, 34 Following this initial phase pyrazinamide and ethambutol are discontinued 
and treatment continues for an additional 4 month period which is known as the 
consolidation phase.34 Together these treatments represent the cornerstone for the 
treatment of drug susceptible MTB infections used clinically. Although the regime 
described above shows efficacy against drug susceptible MTB, drug resistance to all of 
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Rifampin (RMP) is arguably the most important component of the current treatment 
for TB (see Table I-1).  RMP is derived from the ansamycin class of antibiotics discovered 
in extracts from Amycolatopsis rifamycinica found in soil samples from the pine forests of 
the French Riviera.32 RMP, a semisynthetic rifamycin derivative which targets the β-
subunit of RNA polymerase, was a groundbreaking addition to the arsenal of TB 
treatments because it shorted the treatment time for TB infections from 18 months to 9 
months.35  A critical property of rifampin is its sterilization ability which allows it to kill latent 
MTB.35 The exact mechanisms of rifampin function and resistance will be described in 
detail in the next section. 
Another critical component in the treatment regime is isoniazid which inhibits 
mycolic acid biosynthesis, a major component of the mycobacterial outer membrane 
(MOM) section of the MTB cell wall (see Figure I-2).36 Isoniazid is a prodrug which enters 
the cell via passive diffusion. It’s prodrug form is activated by KatG a catalase-peroxidase 
which leads to the formation of reactive oxygen species, superoxide and the isonicotinyl 
radical.37 The former causes cell damage to several macromolecular cell components 
and the isonicotinyl radical covalently modifies NAD+ which leads to the inhibition of FASII 
enoyl-ACP reductase (InhA). This compound has bactericidal effects against actively 
replicating MTB; however, it shows limited efficacy against LTBI.37 Primary resistance to 
isoniazid arises from point mutations in either the katG gene, preventing activation of 
prodrug, or the target inhA gene, preventing interaction of covalently modified NAD 
interaction with InhA.37-38 (see Table I-1). 
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The exact mechanism of action for pyrazinamide still remains unclear; however, 
its specificity for killing of mycobacteria within the Mycobacterium tuberculosis complex 
(M. tuberculosis, M. africanum, and M. microti) and sterilizing capabilities were critical for 
reduction of the time of treatment from 9 months to 6 months in conjunction with RMP.40 
Like isoniazid, pyrazinamide is a prodrug which is converted to its active form, pyrazinoic 
acid, by a bacterial amidase nicotinamidase/pyrazinamidase or Pzase (pncA). In its 
anionic form, pyrazinamide has no antibiotic effects; however, it is actively effluxed and 
protonated in the extracellular matrix, upon reentry into the cell it causes an acidification 
of the cell which leads to cell death.40 Primary resistance to pyrazinamide comes from 
modification of pncA, either from point mutations in the gene or via deletions and/or 
insertions (see Table I-1). Another reported mechanism of resistance has been attributed 
to modification of the pncA promoter, likely altering expression of pncA.41 
Lastly ethambutol is included during the induction phase, mostly as a defense 
against resistance to the other three drugs mentioned above. The exact mechanism of 
action for ethambutol is still unclear but it has been shown to inhibit arabinosyl 
transferase, an enzyme which forms the arabinogalactan component of the MTB cell wall 
(see Figure I-2).42 Its use is limited in children due to toxicity and this drug is associated 
with optic neuropathy further complicating the use in the induction phase.43 Resistance to 
ethambutol occurs through mutations in the embCAB operon which codes for arabinosyl 
transferase. The vast majority of these mutations occur within codons 306-497 of embB, 
with the most frequent occurring at codon 306 (see Table I-1).44 
In 2016, there were 600,000 cases of rifampin resistant (RMPR) cases of MTB 
reported of which, 490,000 were classified as multiple-drug resistant TB cases (MDR-
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TB).6 MDR-TB is defined as MTB which is resistant to both rifampin and isoniazid. A 
majority of these cases occurred in India, China, and the Russian Federation. 
Development of MDR-TB substantially changes treatment time, regimen, and expected 
outcome.6 The WHO recommends a treatment regime lasting at least 20 months for MDR-
TB.34 Reported success rates for individuals with MDR-TB is 50% which is significantly  
lower than the roughly 80% success rate for those with drug susceptible TB.6 Direct 
cost of treatment of TB infection in the USA also increases from on average $17,000 to 
$150,000 with MDR-TB infections (though this number is significantly lower  
in developing countries).45 Several second-line treatments are recommended for 
individuals diagnosed with MDR-TB, these include a fluoroquinolone and at least one  
injectable aminoglycoside such as amikacin (see Table I-2).6, 34, 46 
Table I-2: Second line treatments for Tuberculosis 
A fluoroquinolone such as ciprofloxacin, gatifloxacin, levofloxacin or levofloxacin, 
are recommended for MDR-TB treatment regimes. Fluoroquinolones target bacterial DNA 
replication, more specifically DNA gyrase and topoisomerase IV.47 An addition to a 
Second Line Antibiotics   
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topoisomerase IV 





30S Ribosome subunit 
Disrupts Protein Synthesis 
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fluoroquinolone an injectable aminoglycoside is administered.34 Examples from this 
antibacterial class include amikacin, capreomycin, kanamycin, and streptomycin. These 
antibiotics function by disrupting ribosome function. Addition of these treatments to the 
patient’s regimen can be difficult because many can cause undesirable adverse effects 
which can lead to poor patient compliance.9 Resistance to both of these drug types have 
been reported. Primary resistance to fluoroquinolones occurs from modification to the 
gyrA and gyrB genes encoding DNA gyrase and topoisomerase IV.48 Though the 
mechanisms for each of the aminoglycosides differ slightly, resistance primarily occurs 
through target modification of S12 protein (rpsL), aminoglycoside acetyltransferase (eis) 
or via an inactivating mutation in the 16S rRNA (rrs) (see Table I-2).49 Other second line 
treatments for MDR-TB include ethionamide, D-cycloserine, para-aminosalicylic acid.9 
Clinical isolates which present resistance to all of the antibiotics mentioned up to 
this point are characterized as extensively drug resistant TB (XDR-TB).6 People who have 
this form of TB have a 30% positive outcome (28% die, 21% fail treatment, and 20% are 
lost to follow up). It is estimated that 6.2% of MDR-TB cases are actually XDR-TB and 
this form of TB has been observed in 123 countries with a majority of cases found in 
Ukraine and the Russian Federation.6 Cost for treatment of XDR-TB in the USA 
skyrockets from $150,000 for MDR-TB to nearly $500,000 for XDR-TB.45 Needless to 
say, increasing prevalence of XDR-TB, low efficacy of the current treatment regimen and 
lack of novel treatments represents a critical global health threat. 
As a result of the recognition of the scope of the TB pandemic as a global threat, 
there has been some progress in identifying new antitubercular treatments. In 2012, the 
FDA approved the first new drug for TB in over 50 years, bedaquiline (BDQ), for use in 
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the treatment of MDR-TB.34, 50-51 Bedaquiline is a diarylquinoline which targets subunit C 
of ATP synthase (atpE), blocking energy homeostasis in both replicating and dormant 
MTB.52 Though this new drug has been approved for MDR-TB it remains in Phase III 
clinical trials for unresolved safety concerns (11.4% of patients taking BDQ died in phase 
II trials compared to 2.5% taking placebo).51 Additionally, resistance to BDQ has already 
been reported.  Mutations in atpE have been observed as well as mutations in 
transcriptional regulator Rv0678 which leads to upregulation of efflux pump MmpL.53-54 
Another investigational drug, delamanid has been approved by the European 
Union and Japan for the treatment of MDR-TB but has yet to receive approval from the 
FDA. Delamanid (DLM) is a nitroimidazole which shows efficacy against both actively 
replicating and latent MTB.46, 55 DLM acts by interfering with mycolic acid biosynthesis 
and is activated similarly to pretomanid.  Both are prodrugs which are activated by 
deazaflavin-dependent nitroreductase enzyme (Ddn).55 Resistance to DLM has been 
reported to be due to mutations in both the Ddn and a coenzyme F420 gene (fdg1).53  
There are also several other investigational drugs in the TB pipeline which are in 
early clinical development (see Figure I-3).  Sutezoid, an oxazolidinone, which targets 
the ribosome, is in Phase II clinical trials. Other new treatments include Q203, an 
imidazopyridine and PBTZ169, a piperazine-containing benzothiazinone, both of which 
are in Phase I clinical trials.9, 56 Many of the occupants within the pipeline are not novel 
drugs but new combinations of currently utilized drugs (see Figure I-3). Though some 
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progress has been made in identifying new treatments for drug susceptible and resistant 
TB, there remains an unmet need for novel treatments. 
 
Figure I-3: Pipeline of drugs for the treatment of tuberculosis.56 
Rifampin Resistance 
Rifampin (RMP) has been the cornerstone of all TB treatment regimens since its 
introduction in the 1960’s.  Rifampin is a semisynthetic derivative of rifamycin SV which 
has been modified with a 3-(4-methyl-1-piperazinyl)-iminoethyl modification to improve 
the pharmacokinetic profile.35  The core rifamycin is composed of a napthoquinone which 
has a highly functionalized, poly-hydroxylated ansamycin ring.  RMP and rifamycins are 
highly selective for bacterial DNA-dependent RNA polymerase (RNAP). Bacteria have a 
single DNA-dependent RNA polymerase (RNAP) responsible for the production of all 
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RNA within the cell. RNAP core enzyme is composed of five subunits, two α-subunits 
(RpoA), β-subunit (RpoB), β’-subunit (RpoC), and the ω- subunit (RpoZ).57  Rifampin 
targets a cleft in the β-subunit (RpoB) roughly 20Å from the catalytic center.58  RMP 
functions by binding to free and initiating RNAP, blocking elongation of nascent RNA 2-
3nt from the active center.58 RMP has an affinity 10,000-fold weaker for the eukaryotic 
counterpart, making it a selective antibacterial treatment.  The affinity of RMP for bacterial 
RNAP is in the range of 10-9-10-8 M.59 The surface of the binding cleft in RpoB consists 
of several loops within the 81-residue rifamycin resistance-determining region (RRDR) 
and Fork Loop 2 (see Figure I-4).  The RRDR can be divided into 4 regions: the N-
terminal cluster (residue 146, E. coli numbering), cluster I (residues 507-533), cluster II 




Figure I-4: Sequence alignment spanning the RRDRs of the E. coli, T. thermophilus 
and MTB β-subunits of RNAP. RRDRs are indicated above the amino acid 
sequences. Amino acids that are identical among the three species are 
shown as gray background. Mutations that confer RMPR in E. coli and MTB 
are indicated.60-61 Three major RMPR mutation sites are labeled. Mutations 
unique for E. coli RNAP are shown in blue, mutations unique for MTB RNAP 
are shown in red, and mutations found in both RNAPs are shown in black 






A vast majority of RMP resistant mutations occur within the RRDR (95%) on the 
RpoB (see Figure I-4). Roughly 90 non-synonymous mutations at 33 codons have been 
observed in clinical isolates of MTB with RMPR;59, 62-63 However, amino acid substitutions 
at three codon locations βD435V (MTB numbering), βH445Y, and βS450L comprise 85% 
of RMPR mutants enriched in clinical isolates.59, 64 Within these three genotypes the 
overwhelming majority of isolates carry the βS450L mutation (40-70%).62-63, 65-66  Several 
biochemical studies have been carried out to elucidate the effects of RMPR with E. coli 
RNAP.  Laboratory evolved strains of E. coli RNAP carrying RMPR mutations have been 
produced; however, the profile of RMPR mutations differs between E. coli and MTB (see 
Figure I-4).59 For example, the βS450L mutation is not observed in E. coli isolates 
conferring RMPR 59; however, in E. coli a serine to phenylalanine or tyrosine substitution 
has been observed. One explanation for this observation is for E. coli to evolve Ser to 
Leu it would require two nucleotide substitutions (TCT to TTG/TTA) while in MTB only a 
single point mutation is required (TCG to TTG).67 Of all the 4 nitrogenous bases cytosine 
is the most predisposed to chemical modification. This occurs via deamination to uracil 
which can lead to a C:G to T:A transition.68 These types of mutations are highly 
representative of single point mutations.68 Identification of these specific codon changes 
is the current method for clinicians to diagnose RMPR in clinical isolates via PCR.69 
Mutations found in RRDR and their effects on RNAP function have been 
extensively studied in E. coli. Many studies used phenotypic screening methods to enrich 
mutants which perturb enzyme function, such as ability of the enzyme to initiate, elongate, 
and terminate transcription.60, 70-71 Additionally, RMPR mutations cause pleiotropic effects 
on cellular physiology and metabolism.72 Several secondary metabolism genes are 
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differentially regulated in RMPR mutant MTB.73 For example, polyketide synthase genes 
ppsA, ppsE, and drrA which produce phthiocerol dimycocerosate as well as other lipids, 
which are components of the outer cell wall, are overexpressed.74-75 Altering the 
composition of the cell wall has been shown to alter the permeability of the cell wall.76 
Rifampin resistance is a complex phenomenon which has far reaching effects for both the 
patient and the organism itself and remains a highly studied topic to this day. 
Fitness Defects and Compensatory Mutations 
Fitness is determined by an organism’s ability to survive and replicate (in the case 
of MTB) under a specific set of conditions. Mutations which impart antibiotic resistance to 
the organism can often have deleterious effects on the organism’s overall fitness. The 
most prevalent mutation associated with rifamycin resistance is βS450L in the β-subunit. 
It has been observed that the fitness defects associated with the βS450L RMPR mutation 
vary dramatically between individual isolates, despite carrying the same resistance 
mutation.77-80 This led to the suggestion that there may be other mutations present within 
RNAP which were responsible for fitness variability. Typically, clinicians and research 
scientists focused on sequencing the RRDR when studying RMPR MTB, so until recently, 
there was little information of the genetic nature of other regions of RNAP. Full gene 
sequencing of the subunits of RNAP, most notably the β’-subunit, led to discovery of 





Figure I-5: Compensatory mutation sites. A) Double-psi β-barrel (DPBB) of MTB RNAP 
is highlighted with the DbDGD motif and catalytic Mg+2 (dark blue) and 
compensatory mutations (cyan). The compensatory mutations used in this 
study are denoted in magenta (PDB: 5UHA). B) Sequence alignment of 
MTB, E. coli, and T. thermophilus DPBB. Stars above sequence alignment 
are compensatory mutations. The red stars indicate the compensatory 






The genome sequences of 117 multiple-drug resistant (MDR) MTB, strains which 
exhibit resistance to RMP and isoniazid, and 212 MDR-MTB strains from high-burden 
countries (Georgia, Uzbekistan, and Kazakhstan) were analyzed for the presence of 
mutations in RNAP subunits other than rpoB. Results showed that 30% of the 225 isolates 
that carried the βS450L mutation had an additional mutation in the β’-subunit (rpoC).82  
The presence of these compensatory mutations is overwhelmingly, but not 
exclusively associated with the βS450L RMPR mutation. Roughly 9% of secondary 
mutations were observed in the α-subunit (rpoA), though they all localize in proximity to 
each other spatially.82 Similar results were also observed in two other studies, which 
found that 44% and 54% of isolates from West Cape, South Africa and South Korea, 
respectively, carried a mutation in the β’-subunit/rpoC in addition to the βS450L 
mutation.66 In consecutive isolates obtained from the three separate patients who had 
progressed from MDR- to XDR-MTB over a 6-month period, it was found that all isolates 
from these three patients contained the βS450L mutation with another mutation, 
β’V483G.66 This suggests that these mutations are participating in the progression drug 
resistance in MTB. 
The β’V483G mutation is the most prevalent mutation associated with the βS450L 
mutant and has been observed in all of the studies mentioned above, suggesting it is 
arising by convergent evolution and is physiologically relevant to the organism (see 
Figure I-5).66, 82 Allelic exchange was used to replace the rpoB and rpoC genes in M. 
smegmatis (MSG) with their respective counterparts from MTB containing the βS450L 
and β’V483G or β’F452L. The study revealed that the fitness defect associated with the 
βS450L mutant was fully ameliorated with the β’V483G mutation and partially 
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compensated by the β’F452L mutation and this effect was most dramatic under carbon-
limiting conditions.66 The effect observed under carbon-limiting conditions coupled with 
the localization of the mutations at the double-psi β-barrel, where ppGpp binds suggested 
that these mutations may be involved in the stringent response (see Figure I-5). 
RNA polymerase Structure and Function 
As mentioned above, the bacterial RNAP core enzyme is composed of five 
subunits, two α, one each of β, β’, and ω.57  In MTB there are 13 sigma factors (A-M) 
which, when associated with core enzyme, form the holoenzyme (see Figure I-6 upper 
panel).83 RNAP has been likened to a crab claw, which is composed of a clamp region 
provided by the β’-subunit with the β-subunit forming the pincer. The clamp is dynamic 
region of the protein which can adopt both “open” and “closed” states.57, 84 RNAP is a 
highly complex and dynamic enzyme which requires several complex mechanistic steps 
to occur for the production of RNA (see Figure I-6 lower panel). 
With a cognate sigma factor, RNAP binds promoter DNA, which enters through the main 
channel of RNAP formed by both the β- and β’-subunits (Figure I-5). Core promoter cis-
elements consist of a -10, extended -10, and -35 recognition elements (numbers denoting 
location from the transcription start site or TSS), which are recognized by sigma factor 
region 2.4 (σ2.4), sigma factor region 2.5 (σ2.5), and sigma factor region 4.2 (σ4.2) 
respectively.57 Once RNAP is positioned over the promoter region several isomerization 
steps occur to go from the closed-promoter complex (RPc) to the open-promoter complex 
(RPo), during which promoter DNA is unwound to form the transcription bubble (see 
Figure I-6 lower panel). The transcription bubble extends from +1 to -11 relative to the 
TSS. The RPo stability varies from seconds to minutes depending on several factors 
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including sequence and the presence of secondary transcription factors. At this point 
RNAP is ready to receive nucleotide triphosphates (NTPs), which enter through the 
secondary channel.85-87 As RNAP begins to incorporate NTP into the elongating RNA, the 
initial transcription complex can go through several abortive initiation events where short 
RNA’s are released.88 During this time the sigma factor is retained. Abortive initiation is 
thought to be caused by strong interactions between RNAP and promoter sequences.88 
DNA “scrunching” occurs during abortive initiation, during this process RNAP pulls and 
unwinds DNA into the main channel inducing stress which is thought to overcome strong 
interactions with promoter DNA.89   
After RNAP produces a transcript of roughly 12-15 nucleotides, a structural change 
occurs which are thought to result in the loss of the sigma factor and leads to stabilization 
of the RNAP-DNA-RNA ternary complex and productive RNA synthesis, this is referred 
to the elongation complex (EC).90 (The loss of the sigma factor upon RNAP transition to 
the elongation complex remains contentious, FRET experiments have shown that the 
sigma factor can remain bound to the EC.91) EC’s are highly processive and stable 
complexes which are resistant to challenge by high salt, high temperature conditions, as 
well as, challenge by DNA mimetics such as heparin.92-93 RNAP can elongate for several 
thousand bases before recognition of a termination signal. Bacteria contain both rho-





Figure I-6: Structure of RNAP and kinetics of transcription. MTB RNAP holoenzyme 
(PDB: 5HUA; upper panel). Kinetic steps required for production of mature 
RNA (lower panel).  
 
Structurally, RNAPs have several notable subdomains and structures which aid in 
nucleotide addition. The active center is located at the base of the main channel and is 
where the catalytic Mg2+ is chelated to three highly conserved aspartic acid residues 
which are part of a highly conserved DGDbD motif (b = bulky residue) on the double-psi 
beta-barrel (see Figure I-5).95 The trigger loop (TL) which lies at the center of the main 
channel can adopt multiple conformations which oscillate as nucleotides are incorporated 
into the elongating RNA.96-97 The TL locks nucleotides in the active site, allowing for the 
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formation of the phosphodiester bond between free NTP and the 3’-OH of the elongating 
RNA.97 After incorporation the trigger loop retracts allowing for pyrophosphate to leave 
through the secondary channel. Another motif which plays a significant role in this process 
is the bridge helix (BH), which bifurcates the main channel.98-99 The BH has been 
observed in both a bent and straight conformation in elongating RNAP’s and is thought 
to work in concert with the trigger loop during nucleotide incorporation.100 Lastly the fork 
domain, which is composed of fork loop 1 and fork loop 2, plays a critical role in nucleotide 
incorporation and processive transcription.101 The role of fork region has been debated; 
however, it is clear that it plays a critical role in initiation and elongation.102 Fork loop 2 is 
of particular interest as it adopts several conformations and has been proposed to have 
roles from unwinding DNA to stimulating incorporation of NTPs via fork loop 1.101-102  
Inhibitors of Bacterial RNA polymerase 
RNAP is a proven effective therapeutic target, as demonstrated by the success of 
rifampin. There are several reasons for this which include: 1) there is a single RNAP 
employed by bacteria, which if successfully targeted prevents all RNA related function 
within the cell, 2) RNAP’s are highly conserved among bacteria, which allows for potential 
broad-spectrum antibiotic activity, and 3) bacterial RNAP’s share little sequence similarity 
to eukaryotic RNAPs allowing for selectivity. Currently there is only one other RNAP 
inhibitor on the market in addition to rifampin, fidaxomycin (also known as lipiarmycin), 
which is limited to treatment of gastrointestinal infections caused by gram positive 
pathogens (primarily Clostridium difficile) due to poor systemic bioavailability. Although 
there are few marketed RNAP inhibitors there are a significant number of bacterial RNAP 
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inhibitors which have wide ranging mechanisms of action and spatially distinct binding 
sites within RNAP (see Figure I-7). 
The switch region of RNAP which aids in clamp closure around DNA is the site of binding 
for several known RNAP inhibitors (see Figure I-7).84, 103 The function of the switch 
domain gives a clue to the mechanism of action of these inhibitors. Upon binding of RNAP 
to DNA it is in the “open” conformation, structural changes within the switch domain 
induce closure of the clamp over the DNA leading to a “closed” conformation.103 
Fidaxomicin is a natural product produced by Dactylosporangium aurantiacum which 
binds within the switch domain preventing the closure of the clamp domain around DNA.84 
In vitro characterization of Fidaxomicin has shown that it has a modest effect on Gram 
negative RNAP (7 μM in E. coli and MTB).104 However, recent work has shown that the 
transcription factor RNA polymerase binding protein (RbpA) is required for high potency 
inhibition with Gram negative bacterial RNAP (0.21 µM).104  
There are a set of switch domain inhibitors which act oppositely to Fidaxomicin, 
stabilizing the closed conformation of the clamp, preventing double stranded DNA from 
entering the main channel. Myxopyronin, corallopyronin, and ripostatin bind a 
hydrophobic cleft near switch 1 and switch 2, locking the clamp in the closed 
conformation.103 Though ripostatin is structurally dissimilar to both myxopyronin and 
corallopyronin they share the same binding cleft.103 Another set of molecules which bind 
a similar region of RNAP are the squaramides.  The squaramides were identified in a 
coupled transcription-translation assay.105 These compounds act by shifting switch 2 into 




Figure I-7: Inhibitors of RNA polymerase and functional region of RNAP which 
they target.  
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The main channel of RNAP is host to many inhibitors as well (see Figure I-7). 
Sorangicin, a macrocyclic compound isolated from Sorangium cellulosum occupies the 
same binding site as rifampin.107-108  Adjacent to the rifamycin site, in the direction of the 
active site is where the cyclic peptide natural product GE23077 binds.109 This macrocyclic 
heptapeptide occupies the i and i + 1 sites. Its large size has limited its efficacy due to 
issues with permeability, but conjugates with rifampin showed efficacy against both wild-
type and RMPR mutant RNAPs in vitro, which suggests if permeability issues could be 
resolved this could be a promising lead for the treatment of RMPR MTB.109 Recently, the 
nucleoside analog inhibitor, pseudouridimycin (PUM), was identified from a microbial-
extract screen. This inhibitor occupies the active site and competes with UTP.110  
Within the main channel there are several dynamic motifs, including the bridge 
helix and trigger loop, and these also are binding sites for several RNAP inhibitors (see 
Figure I-7). Streptolydigin is a natural product which targets elongating RNAPs. It binds 
adjacent to the bridge helix and trigger loop preventing conformation changes of both 
required for nucleotide incorporation.111 Salinamide A and E (Sal) are bicyclic 
polypeptides which were isolated from Streptomyces spp. and target RNAPs from both 
Gram negative and positive pathogens. Sal binds in a region between the secondary 
channel and the bridge helix and is thought to disrupt the function of the bridge helix, 
preventing nucleotide addition.112 The CBR series of small molecules were identified in 
an in vitro E. coli transcription screen. These small molecules stabilize the elongation 
complex slowing down translocation by allosterically modulating both the trigger loop and 
bridge helix.113 Nα-aroyl-N-phenylalaninamides (AAP’s), identified in a separate screen, 
bind similarly to the CBR analogs.114 
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There are several inhibitors which target the secondary channel as well as other 
sites on RNAP (see Figure I-7). Tagetitoxin, a natural product isolated from 
Pseudomonas syringae pv. Tagetis, shows activity for both prokaryotic and eukaryotic 
RNAPs.115 A structure of tagetitoxin with T. thermophilus shows that it binds the 
secondary channel, however it has been proposed to also interact with the trigger loop.116 
Microcin J25 is a 21-mer peptide which prevents NTPs from entering the active site, 
shows activity against E. coli RNAP.117 MRL-436 is a small molecule identified from a 
mass spectrometry-based screen.118 MRL-436 has been shown to bind to the same site 
as ppGpp, a small molecule involved in the stringent response, adjacent to the ω-
subunit.118 The exact mechanism of this molecule is still unknown; however, because of 
its proximity to the ppGpp site suggests it potentially destabilizes the open-promoter 
complex.118  
All of the inhibitors mentioned up to this point have targeted core RNAP (see 
Figure I-7). Several inhibitors have been identified which target the interaction between 
core RNAP and the sigma factor. DSHS00507 was identified in in silico screening was 
shown to prevent sigma factor association with RNAP by binding to the β’-subunit CH 
region.119 The SB small molecules series of small molecules was identified in a ELISA 
based assay using E. coli RNAP were also shown to disrupt holoenzyme formation.120 
Lastly the GLK series of small molecules which bind to the same motif as the SB series 
were identified via a structure-based design using amino acid interactions between RNAP 
and the sigma factor to generate a pharmacophore model.119, 121 RNAP has been 
extensively targeted for drug development; however, targeting of trans-acting factors 
which contribute to the function of RNAP has not be extensively attempted. The only 
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transcription factor which has been successfully targeted is rho, a termination factor. 
Bicyclomycin, a natural product derived from Streptomyces sapporonensis, prevents 
Rho-dependent termination and ATP hydrolysis.122 The development of therapeutic 
agents which target transcription factors represents a gap in the efforts to inhibit 
transcription. 
Mycobacterial Transcription Regulator CarD 
CarD is a global transcriptional regulator found in certain groups of both Gram 
positive- and Gram-negative bacteria.85, 123-125 After RNAP binds to a promoter, forming 
the closed complex (RPc), the transcription bubble/open promoter complex (RPo) is 
formed by unwinding the DNA allowing RNA to be transcribed. This step is thought to be 
the rate limiting step for gene expression. CarD stabilizes the open-promoter complex.85, 
126-127 Stabilization of this complex is essential for MTB viability; attempts to remove CarD 
from the MTB genome were lethal.128-130 However, conditional depletion of CarD using a 
tetracycline-controlled gene expression led to increased sensitivity to reactive oxygen 
species and RMP, as well as the inability of MTB to replicate and persist in mice.128 Many 
of the mutations in CarD which were attempted to be introduced through homologous 
recombination were not tolerated which suggests that small changes in protein structure 




The N-terminal domain of CarD interacts with the β1β2-lobes on the β-subunit of 
RNAP, which is proximal to Rif binding site (see Figure I-8). Crystallographic data 
suggests that a conformational change induced by CarD binding may modulate RMP 
affinity.131 Additionally, weakening of the interaction between CarD and RNAP resulted in 
increased MTB susceptibility to RMP, consistent with a conformational linkage between 
the CarD and Rif binding sites.130 This may suggest that development of therapeutics 
which inhibit the CarD•RNAP interaction might also improve RMP efficacy. 
CarD homologues are present in many bacterial phyla, making it an attractive 
therapeutic target.85 Notable Phyla (disease states) which carry CarD proteins include: 
Chlamydiae (chlamydia), Firmicutes (C. diff. colitis), Rikettsia (typhus) and Spirochaetes 
 
Figure I-8: Interaction of CarD with RNAP. Structure of T. aquaticus (Taq) RNAP 
(PDB: 4XLR) open-promoter complex with Taq CarD (Cyan) 
superimposed with MTB β1β2-lobe (hidden) and MTB CarD (red PDB: 
4KBM). The structure is rotated out of the plane of the paper to show the 
contacts of the Taq CarD (Cyan) with the upstream fork junction of the 
transcription bubble. MTB is in the “out” conformation and Taq CarD in the 
“in” conformation, making contacts with both RNAP and promoter DNA. 
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(Lyme disease) in addition to other clinically relevant pathogens. With this in mind, it is 
our belief that CarD represents an appealing target for therapeutic discovery for the 
treatment of tuberculosis as well as other clinically relevant pathogens. 
Research Objectives 
 MTB RNAP polymerase represents an attractive and proven therapeutic target for 
novel antibiotic discovery. The main goals of this dissertation were three-fold: 1) to obtain 
highly pure and active recombinant MTB RNAP, 2) to use this purified enzyme to 
characterize clinically relevant MTB RNAP’s both mechanistically and kinetically, to gain 
a better understanding of rifampin-resistance, and 3) to look for novel approaches to 
target transcription in MTB via CarD, a transcriptional regulator, for future novel 
therapeutic potential. Over the course of this project, we have gained insight into MTB 
RNAP function and have been successful in priming and developing CarD for therapeutic 
discovery. The primary objectives described in each chapter are as follows: 
Chapter 2: To overexpress, purify and characterize MTB RNA polymerase. 
 Using multiple expression plasmids, an in vivo reconstituted MTB RNAP 
purification was optimized for the recovery of highly pure and active enzyme. Purified 
enzyme was used to identity the IC50 of rifampin for WT and RMPR MTB RNAPs. This 
work was complemented with structural information about the RMPR mutant RNAPs using 





Chapter 3: To characterize clinically relevant Rifampin Resistant M. tuberculosis 
RNA polymerases In vitro  
 Using purified MTB RNAP enzymes several in vitro RNA transcription assays were 
utilized to probe initiation, elongation, termination, and 3’-RNA hydrolysis with the wild-
type and RMPR MTB RNAPs. We found that the less prevalent RMPR mutants exhibit 
significantly poorer termination efficiencies relative to wild-type, an important factor for 
proper gene expression. We also found that several mechanistic aspects of transcription 
of the RMPR mutant RNAPs are impacted relative to wild-type. 
Chapter 4: To development, optimize and execute a Fluorescence Polarization 
assay to Identify Inhibitors of MTB Transcriptional Regulator CarD via HTS 
 A fluorescence polarization to monitor the binding of MTB transcriptional 
regulator CarD to the RNAP•DNA ternary complex was developed and optimized. Using 
this assay both a 237 and 23,320 compound HTS were conducted. Hits were 
characterized using biochemical, biophysical, and bacterial techniques to identify novel 
inhibitors of both the CarD interaction with the RNAP•DNA ternary complex and 
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Construction, Expression, and Purification on M. tuberculosis RNA polymerase 
MTB RNA polymerase (RNAP) is the target of rifampin (RMP), a first line treatment 
for TB. Rifampin binds to the β-subunit or rpoB of RNA polymerase (RNAP) preventing 
elongation of the nascent RNA transcript. The increased prevalence of rifampin 
resistance (RMPR) continues to make treatment options more challenging.1,2  Three 
mutant RNAPs (βD435V, βH445Y, and βS450L) together represent roughly 80% of RMPR 
alleles found in clinical isolates, with the βS450L mutant representing the majority of 
mutants observed.3,4,5,6  MTB RNAP is an ideal target for drug discovery because while 
sequence similarity among bacterial RNAPs is high, they structurally diverge from their 
eukaryotic counterparts. A single DNA-dependent RNAP is responsible for all RNA 
synthesis within bacteria. To study the therapeutic potential of RNAP for the treatment of 
TB, highly pure and active RNAP is required. 
Several bacterial RNAPs have been successfully overexpressed and purified.7-12 
Most structural and biochemical studies use Thermus aquaticus (Taq) and E. coli RNAP, 
though other bacterial RNAPs have been successfully purified. Taq RNAP is useful for 
studies involving highly conserved motifs within bacterial RNAP such as catalytic center; 
however, there are significant sequence differences in regions of RNAP distal to the 
active center.  E. coli RNAP has been purified and characterized for nearly 50 years and 
has become the gold standard for bacterial RNA polymerase studies involving drug 
discovery. Efficient expression and purification protocols are available for acquiring large 
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quantities of E. coli RNAP, the success of which is likely due to the homologous 
overexpression. Acquisition of other bacterial RNAPs via heterologous expression in E. 
coli has been more challenging. 
For more thorough studies involving MTB RNAP function, the use of endogenous 
RNAP from MTB would be ideal. E. coli RNAP shares roughly ~40% sequence similarity 
with MTB RNAP (though the RMP binding cleft shares nearly 95% sequence similarity), 
so there are likely differences in both protein structure and function which may limit efforts 
to use E. coli in MTB drug discovery efforts. This has been shown to be especially true in 
the case of open-promoter complex studies.13 Promoter complex studies show that MTB 
RNAP forms a much less stable open-promoter complex than the E. coli RNAP. 
Therefore, in order to improve the biochemical information about RNAP function, MTB 
RNAP should be used for mechanistic studies and drug discovery for TB therapeutics. 
 Several attempts to generate purified MTB RNAP have been attempted. These 
include production and isolation of MTB RNAP from MTB.14 While purified enzyme was 
obtained using this method, it requires a laboratory meeting Biosafety Level 3 (BSL3) 
protocols. Additionally, MTB is a slow growing organism with a doubling time of nearly 24 
hours so it takes several weeks to obtain cultures. Other methodologies employed to 
obtain MTB RNAP include overexpressing each of the subunits separately and 
reconstituting the RNAP in vitro.15 The issue with this method is a significant amount of 
the reconstituted protein was inactive, likely due to aggregation, misfolding of purified 
subunits, and misassembly of RNAP complex.  
Herein, efforts to obtain pure and active MTB RNAP are discussed. A method 
previously developed to overexpress MTB from a polycistronic vector encoding the core 
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subunits of MTB RNAP are discussed.16 A newly developed method, where multiple 
plasmids encoding multiple MTB core subunits as well as the primary sigma factor, SigA, 
are also described.17 The effect of the RMPR mutations in the RRDR on RMP potency are 
also explored. 
Materials and Methods 
Plasmid and DNA Manipulation 
 pMTBRP-5,6,7,8 were all constructed as previously described.16 MTB RNAP Duet-
expression vectors were constructed as follows. Genes encoding RpoB (β-subunit) and 
RpoC (β’-subunit) were amplified for construction of pET-rpoB(C-terminal His10X)-rpoC, 
containing a C-terminal decahistadine-tag on the RpoB gene, from pMTBRP-5 using 
primers rpoB AMP FOR and rpoB AMP REV and rpoC AMP FOR and rpoC AMP REV 
respectively ( all construction primer are available in Appendix Table II-A1). For RMPR 
mutants βD435V, βH445Y, and βS450L the rpoB genes were amplified from pMTBRP-6, 
pMTBRP-7, and pMTBRP-8 respectively using the primers mentioned above for the 
amplification of the WT rpoB gene. Amplified rpoB was digested with NcoI and BamHI 
and rpoC was digested with NdeI and EcoRV and subcloned into alkaline phosphatase 
(CIP) treated pET-Duet which was digested with the corresponding digestive enzymes. 
The rpoB gene was subcloned first into pET Duet followed by rpoC.  
pAcYc-rpoA-rpoZ, encoding RpoA and RpoZ, was constructed by amplifying rpoA 
and rpoZ from pMTBRP-5 using rpoA AMP FOR and rpoA AMP REV and rpoZ AMP FOR 
and rpoZ AMP REV. The same methodology which was used for the construction of pET-
rpoB(C-terminal His10X)-rpoC was used for pAcYc-rpoA-rpoZ. pRSF-SigA, encoding MTB 
SigA, was produced by amplifying sigA from H37Rv gDNA using SigA AMP FOR and 
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SigA AMP REV, restriction digest of the amplified DNA, and ligation into CIP treated pRSF 
using the NcoI and MfeI restriction sites. All DNA fragments and digested vectors were 
gel purified on agarose gels and extracted with Qiagen Gel Extraction kit as directed by 
the manufacturer prior to each ligation step. 
 To produce the pET-rpoB-rpoC, which contains no decahistadine-tag the rpoB 
gene was removed by restriction digest and replaced by the rpoB gene which does not 
contain the histidine affinity tag. The rpoB gene was amplified using rpoB AMP 2 FOR 
and rpoB AMP 2 REV. A hexahistidine-tag was inserted at the N-terminus of the rpoA 
gene by amplifying the rpoA gene with rpoA FOR NThis and rpoA AMP REV from pAcYc-
rpoA-rpoZ, digesting the DNA fragment with BamHI and HindIII, and ligating into CIP, 
BamHI, and HindIII treated pAcYc-rpoZ.  
 To produce pAcYc-rpoA(N-terminal His10X)-SigA, rpoA was amplified with rpoA 
N10his FOR and rpoA AMP REV, digested with NcoI and HindIII, and ligated into pAcYc 
which was treated with NcoI, HindIII, and CIP. The sigA gene was amplified from pRSF-
SigA with SigA NdeI AMP FOR and SigA KpnI AMP REV and treated with NdeI and KpnI. 
Digested DNA fragment was ligated in CIP and restricted pAcYc-rpoA(N-terminal His10X). 
pRSF-rpoZ was produced by amplifying rpoZ from pAcYc-rpoA-rpoZ with primers rpoZ 
NcoI AMP FOR and rpoZ MfeI AMP REV and processed in the same fashion as pRSF-
SigA mentioned above. All plasmids mentioned above were sequenced at the University 
of Michigan Sequencing core. 
Protein expression and purification 
Initial attempts of expression and purification of MTB RNAP core from pMTBRP-
5,6,7,8 were performed as previously described.16 Expression and purification of MTB 
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RNAP core and holoenzyme using the Duet expression system were performed using the 
same methodology used for the pMTBRP expression system with the following difference.  
For acquiring core MTB RNAP pET-rpoB(His10X)-rpoC and pAcYc-rpoA-rpoZ, plasmids 
were transformed into BL21(DE3) chemically competent E. coli in the presence of 
carbenicillin and chloramphenicol. When holoenzyme was produced both previously 
mentioned plasmids, in addition to pRSF-SigA, were transformed into BL21(DE3) 
chemically competent E. coli and grown to an OD600 of 0.4 before cooling to room 
temperature and inducing with 0.5mM IPTG for 16 hours and 16°C. Separation 
techniques for early attempts to acquire purified protein utilized immobilized metal affinity 
chromatography (IMAC) and gel filtration (see Appendix Figure II-A1). 
Final protocols for the purification E. coli and MTB RNAP holoenzymes used for 
all in vitro biochemical assays were prepared as follows. WT and RIFR MTB RNAP 
holoenzymes were overexpressed in BL21(DE3) cells transformed with the three 
plasmids: pET-rpoB-rpoC, pAcYc-rpoA(N-terminal His10X)-SigA,  and pRSF-rpoZ. E. coli 
RNAP holoenzymes were overexpressed from the plasmid pVS10 and pRSF-Sig70 in 
terrific broth supplemented with 1 mM ZnSO4 and induced as described in Banerjee et 
al,17 with the addition of a second plasmid, pRFS-Sig70 encoding rpoD. BL21(DE3) cells 
transformed with the WT or RIFR MTB RNAP holoenzyme expression vectors were grown 
to an OD600 of 0.4 in terrific broth supplemented with 1 mM ZnSO4 and induced with 0.5 
mM IPTG for 16 hours at 16 °C.  Cell pellets from 2L of culture were resuspended in 20 
mL lysis buffer (20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 20 µM ZnCl2, 5% glycerol, 2 mM 
β-mercaptoethanol, 1 mM PMSF and 1X Roche cOmplete ULTRA protease cocktail). 
Cells were lysed by sonication and clarified by centrifugation at 25,000xg for 45 min. The 
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RNAP•DNA complexes were precipitated by addition of polyethyleneimine (pH 7.9) to 
0.6% followed by centrifugation at 6,000xg for 10 min. The pellet was resuspended in 12 
mL lysis buffer containing 500 mM NaCl, followed by centrifugation at 6,000xg for 10 min. 
After centrifugation again and discard of the supernatant, the RNAP was solubilized in 20 
mL lysis buffer containing 1 M NaCl. The RNAP was precipitated by adding ammonium 
sulfate (0.3 g/mL of solution) followed by a 60 min incubation at 4°C. The RNAP 
precipitate was pelleted by centrifugation (6,000xg for 10 min) and the ammonium sulfate 
pellet was resuspended, sterile filtered, and dialyzed overnight (20 mM Tris-HCl (pH 8.0), 
75 mM NaCl, 20 µM ZnCl2, 5% glycerol, 2 mM β-mercaptoethanol).  
The dialyzed RNAP solution was applied to a 5 mL Source 15S cation exchange 
column (GE Healthcare) in TGEB (10 mM Tris-HCl (pH 8.0), 5% glycerol, 0.1 mM EDTA, 
5 mM β-mercaptoethanol) with 50 mM NaCl and eluted over a linear gradient to 1 M NaCl. 
Isolated holoenzyme was then further purified on a 5 mL HisTrap HP column. RNAP was 
applied to the column in 10 mM Tris-HCl (pH8.0), 20 mM NaCl, 5% glycerol, 5 mM β-
mercaptoethanol and eluted over a linear gradient to 500 mM imidazole. The peak 
containing holoenzyme was then applied to a 5 mL Source 15Q anion exchange column 
(GE Healthcare) in TGEB with 50 mM NaCl and eluted over a linear gradient to 1 M NaCl.  
Purified RNAP holoenzyme was dialyzed into storage buffer (40 mM Tris-HCl (pH 7.9), 
200 mM NaCl, 0.1 mM EDTA, 1 mM MgCl2, 20 µM ZnCl2, 50% glycerol, and 5 mM DTT) 






Primer extension Assays 
Determination of the concentration of active RNAP was conducted using a 
DNA•RNA scaffold that mimics the transcription elongation complex.18 First, an 8 
nucleotide RNA (IDT technologies) was labeled at the 5’ end with [γ-P32 GTP (Perkin 
Elmer) using T4 polynucleotide kinase (New England Biolabs). Next, the T4 
polynucleotide kinase was heat inactivated. The DNA•RNA duplex scaffolds were 
prepared by mixing equimolar amounts of template DNA (5’-
CTGAAATCGACATCGCCGCTCAACAT-3’) and 5’-labeled RNA (5’-GCGGCGAU-3’),  
heating to 85 °C for 10 min, followed by slow cooling to room temperature. The elongation 
complex was formed by mixing equimolar RNAP with the DNA•RNA duplex scaffold in 
reaction buffer at 28 °C for 20 min. The reaction buffer for the E. coli RNAP consisted of 
40 mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2, 8 mM DTT, 0.01% Triton X-100 and 
for the MTB RNAP was 40 mM Tris-HCl (pH 7.9), 40 mM potassium glutamate, 0.1 mM 
EDTA, 10 mM MgCl2, 25 µg/mL BSA, 1 mM DTT; both reactions contained 15 mU of 
inorganic pyrophosphatase (New England Biolabs). The primer extension reaction was 
conducted for 10 min after adding the next incoming GTP (400 μM final concentration) to 
the elongation complex. RNA extension was stopped by adding an equal volume of 2x 
RNA loading buffer (95% formamide, 0.025% SDS, 0.025% bromophenol blue, 0.025% 
xylene cyanol FF, 0.025% ethidium bromide, 0.5 mM EDTA – Thermo Scientific). RNAs 
were resolved by gel-electrophoresis in 20% acrylamide (19:1), 7 M urea gel with 1x TBE. 
The gels were processed using a PhosphorImaging cassette (Typhoon 8600 scanner) 




In Vitro Transcription Assays 
An in vitro plasmid based transcription assay using a Malachite Green Aptamer 
(MGA) gene that was previously developed for high-throughput screening was modified 
for these studies.19  Individual modified pTZ18U vectors containing the E. coli rrnB P1 (-
66 to +5) and MTB rrnA P3 (-55 to +15) ribosomal RNA promoters followed by 4 
consecutive repeats of DNA encoding the MGA and three consecutive repeats of the 
synB artificial terminator sequence were prepared, pMGA4-Ec-rrnB1-SynBx3 and 
pMGA4-Mt-rrnA3-SynBx3, respectively. The synB terminator was shown to terminate 
transcription with a 88% and 98% termination efficiency for E. coli and M. bovis RNAPs, 
respectively 20. 
The buffer for determining the RMP IC50s for the E. coli RNAP holoenzymes was: 20 
nM pMGA4-Ec-rrnB1-SynBx3, 40 mM Tris-HCl (7.5 at 22 °C), 50 mM KCl, 10 mM MgCl2, 
0.01% Triton X-100, 1 mM DTT, 500 µM each NTP. For MTB RNAP holoenzymes, 50 nM 
pMGA4-Mt-rrnA3-SynBx3, 40 mM Tris-HCl (pH 8.0 at 37°C), 150 mM potassium 
glutamate, 10 mM MgCl2, 0.1 mM EDTA, 25 μg/mL BSA, 1 mM DTT, 500 µM each NTP 
was used.  For WT E. coli and MTB RNAPs, 10 nM of holoenzyme was used, and for 
RMPR E. coli and MTB RNAPs, 100 nM enzyme was used.  In all cases a 3-fold excess 
of the corresponding purified σ factor was also added.  RMP added to the assays was 
dissolved in DMSO; therefore, DMSO was added to a final concentration of 4% (which 
had a negligible effect on the assay) in all assays.19  RMP was allowed to incubate with 
holoenzyme for 30 min prior to the addition of template DNA and NTPs. Reactions were 
incubated at 37°C for 90 min, followed by quenching on ice with addition of ice cold 
malachite green (MG) in water to a final concentration of 75 µM MG. Fluorescence was 
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detected at excitation and emission wavelengths of 628 nm and 660 nm, respectively, 
using a BioTek Synergy H1 plate reader. The fluorescence readings were normalized to 
% activity, plotted against the log [RMP] and fit by nonlinear regression to Eq. (1) where 
M0 = log of compound concentration, M1 = log of IC50, M2 = hill slope, M3 = lower limit of 
the curve, and M4 = upper limit of the curve.  Three replicate sets of data for each RNAP 
were individually fit and the averages and standard deviations of the three individual IC50s 
are reported in Table 1.  For clarity of visualization, the average % activity for each [RMP] 
were plotted, with their standard deviations as error bars. The final concentrations of the 
WT RNAPs were 10 nM, therefore the minimum IC50 which can be determined for both 
E. coli and MTB WT RNAPs was 5 nM. 




To determine contamination by chromosomally-encoded WT E. coli RNAP, 
transcription assays for the MTB and E. coli RMPR RNAP mutants were conducted in the 
presence and the absence of 200 nM RMP. The results indicate that such contamination 
in MTB RNAP preparations is negligible, while ~25% of E. coli RIFR RNAP preparations 









Preparation and characterization of MTB RNAPs from pMTBRP-5 
Initial attempts at acquiring purified MTB RNAP used a single expression vector 
pMTBRP-5, under control of a single T7 promoter upstream of the α-subunit or RpoA (see 
Figure II-1A). The system produces a >15 kilobase polycistronic mRNA which encodes 
all subunits of core RNAP.21 The only overexpressed MTB RNAP subunit which could 
visually identified was the α-subunit (see Figure II-1B). Enrichment of target protein using 
IMAC chromatography resulted in low yield and samples with poor purity. Several 
methods were explored to improve overexpression of genes downstream of rpoA. These 
include optimization of the ribosome binding sites (RBS), removal of rare codons, and 
insertion of additional T7 promoter/lac operon sites upstream of each subunit. 
  
.  
Figure II-1: Overexpression of MTB RNAP with pMTBRP. A) pMTBRP plasmid map. 






Preparation of MTB RNAP from the Duet Expression System 
For preparing WT and RMPR mutant MTB RNAPs, we used an overexpression 
system in a E. coli host strain 16-17, which utilize vectors carrying the genes of the RNAP 
subunits, under control of a strong T7 promoter. Our first generation of MTB expression 
vectors expressed the RpoB and RpoC on a single plasmid (pET) and RpoA and RpoZ 
on a second plasmid (pAcYc). When holoenzyme was desired a third plasmid (pRSF) 
containing MTB SigA was added in addition to the pET and pAcYc vectors. A 
decahistidine affinity tag was present on the C-terminus of RpoB (see Figure II-2A).  
 
Figure II-2: Purification of MTB RNAP with 1st-generation Duet Expression System. 
A) The three co-expression vectors used to produce MTB holoenzyme with 
a C-terminal decahistadine tag on the β-subunit. B) SDS-PAGE of 
purification methodology used to acquire MTB RNAP holoenzyme. 
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Overexpression of all MTB RNAP subunits can be observed in induced cell lysates 
with the exception of the ω-subunit. MTB RNAP could also be immobilized, washed, and 
eluted using NTA-Ni2+ agarose resin. As a final polishing step MTB RNAP is further 
purified using gel filtration (GF) on a HiPrep Sephacryl S-200 HR column. Though a 
significant amount of MTB RNAP was obtained using this methodology (2-5 mg of protein 
per L culture) a significant amount of contaminating proteins remained present after the 
final purification step (see Figure II-2B). Additionally, the ω-subunit was not observed in 
the final preparation. In E. coli RNAP crystal structures the N- and C-terminus of the β- 
and β’-subunit coalesce in proximity to the site where the ω-subunit associates with 
RNAP. Concerns that the His-tag on the C-terminus of the β-subunit could be interfering 
prompted switching the location of the His-tag to the N-terminus of the α-subunit (see 
Figure II-3A). 
Our co-expression system was modified by removal of the histidine tag from the 
C-terminus of rpoB on pET-rpoB(Hisx10)-rpoC to make pET-rpoB-rpoC and addition of a 
N-terminal hexahistadine tag on the rpoA to make pAcYc-rpoA(His6X)-rpoZ. Switching the 
placement of the histidine tag resulted a large stoichiometric excess of α-subunit in final 
preparation. Again, the ω-subunit was not observed in final preparations. Contaminating 




Figure II-3: Purification of MTB RNAP with 2nd-generation Duet Expression System. 
A) The three co-expression vectors used to produce MTB holoenzyme with 
a N-terminal hexahistadine tag on the α-subunit. B) SDS-PAGE of 
purification methodology used to acquire MTB RNAP holoenzyme. 
The 3rd generation of co-expression vectors used pETrpoB-rpoC; however, the 
sigA gene was exchanged with rpoZ and the hexahistidine tag on rpoA was extended to 
a decahistadine tag (see Figure II-4A). Additionally, our purification protocol was 
significantly altered to improve the quality and stoichiometry of the final purified product 
(see Figure II-4B, Appendix Figure II-A1). The polyamine P precipitation and 
ammonium sulfate steps were retained in the final purification method. Since the α-
subunit was overexpressed in such high quantities, the first chromatography step was 
cation exchange chromatography (see Appendix Figure II-A2). RNAP holoenzyme is 
retained on the Source 15S column, allowing core and excess α-subunit to be removed 
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from the sample. The second chromatography step was IMAC using a HisTrap HP 
column (see Appendix Figure II-A3). This led to further enrichment of MTB RNAP and 
removed endogenous E. coli RNAP. The last polishing step used anion exchange 
chromatography. MTB RNAP eluted as two peaks from the Source 15Q column, the 
second peak had a higher activity and the ω-subunit was also present in the sample (see 
Appendix Figure II-A4). The stoichiometry of the subunits was also similar to the 
theoretical values. The resulting protocol produced highly pure RNAP with a high level of 
catalytic activity. 
Figure II-4: Purification of MTB RNAP with 3rd-generation Duet Expression System. 
A) The three co-expression vectors used to produce MTB holoenzyme with 
a C-terminal decahistadine tag on the β-subunit. B) SDS-PAGE of 
purification methodology used to acquire MTB RNAP holoenzyme. 
62 
 
Determination of percent of catalytically active RNAP from purifications 
 To determine the percent of active RNAP complex in a given preparation, a single 
nucleotide turnover assay using an elongation complex mimetic was used (see Figure II-
5).18 Initial purification methods produced RNAP with <10% catalytically competent 
complex. Literature which purported that a zinc-binding domain in the β’-subunit played a 
significant role in protein folding and assembly led to supplementation of growth media 
with ZnSO4.22 MTB RNAP holoenzyme produced from these cultures ranged from 40-
70% active complex. E. coli RNAPs were 80-100% active. 
 
Figure II-5: Determination of percent active complex via primer extension assay. A) 
5’-32P-RNA/DNA scaffold used for primer extension experiments. B) Activity 
of WT and RMPR E. coli RNAPs. C) Activity of WT and RMPR MTB RNAPs 
before (left) and after (right) supplementation of growth media with ZnSO4. 
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Determination of IC50 of Rifampin with MTB and E. coli, WT and RMPR RNAPs 
In vitro characterization of both MTB and E. coli RNAPs were performed in a 
fluorescence-based plasmid assay. Two plasmids were used to characterize each 
organism’s respective RNAP, one with the MTB rrnAP3 promoter and the other with the 
E. coli rrnBP1 promoter. Downstream of each promoter is four repeats of a malachite 
aptamer sequence which, when transcribed, adopts a secondary structure which has high 
binding affinity for malachite green. Binding of malachite green to aptamer prevents 
vibrational deexcitation of malachite green resulting in a >2000-fold increase in 
fluorescence. Downstream fo the malachite green aptamer coding region, there are three 
consecutive synthetic terminators (synB).20 These terminators prevent RNAP from 
circling the entire plasmid, which could potentially circumvent identification of inhibitor 
effects which occur during initiation.  
The transcriptional activities of the WT RNAPs from E. coli and MTB are completely 
inhibited with 200 nM RMP, whereas the activities of RMPR RNAPs are not influenced by 
RMP at this concentration. Transcription assays of the RMPR RNAP mutants in the 
presence and the absence of 200 nM RMP indicated that contamination by 
chromosomally-encoded E. coli RNAP in the purified MTB RMPR RNAPs is negligible, 
while the E. coli RMPR RNAPs had ~25% contamination (see Appendix Figure II-A4).  
The effect of RNAP mutation on the RMP sensitivity was evaluated by determining 
the IC50 values for RMP using a promoter-dependent transcription assay with RNAP 
holoenzymes (E. coli σ70 holoenzyme and MTB σA holoenzyme). Three RMPR mutants 
tested in this study are classified into two groups according to their RMP sensitivities; the 
D516V and S531L mutants of E. coli RNAP are less sensitive to RMP (IC50 398 and 263 
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µM, respectively), whereas the H526Y mutation makes this enzyme essentially 
insensitive to RMP (IC50 ≥ 2 mM). Corresponding RMPR mutations in MTB RNAP were 
also classified into the same groups; the D435V and S450L mutants are less sensitive to 
RMP (IC50 880 and 789 µM, respectively), whereas the H445Y mutant is essentially 
insensitive to RMP (IC50 > 2 mM, or the solubility limit)23 (see Figure II-6, Appendix 
Figure II-A5). These results support the use of the E. coli RNAP as a model of the MTB 
RNAP in probing molecular mechanisms of RIF resistance. 
Figure II-6: Inhibition of WT and RMPR MTB RNAPs by rifampin. A) Structure of 
rifampin with key sites of interaction with RMPR mutations highlighted. B) 





Structural basis for resistance conferred by the RifR Mutations in E. coli 
In WT RNAP and the RNAP•RMP complex, the D516 (D435 in MTB) residue forms 
part of the sidewall of the RMP binding pocket and assists in positioning RMP to form two 
hydrogen bonds between the F514 main chain (both amino and carboxyl groups) and the 
RMP ansa bridge (OH at C23, O9 atom and keto oxygen at C35, O8 atom) (see Figure 
II-6A). The D516 side chain also contributes to RMP binding by van der Waals 
interactions with the RMP ansa bridge around position C20 and/or by charge 
neutralization of basic residues (R529 and R687) in the RIF binding site to facilitate 
binding the relatively apolar RMP (see Figure II-6A). There is no major structural change 
in RRDR cluster I in the D516V mutant. The structure of the D516V RNAP•RMP complex 
is also similar to the WT RNAP•RMP complex. A significant difference between the WT 
and D516V RNAPs is the electrostatic distribution of the RMP binding pocket around C17 
to C20 of the RMP ansa bridge, which becomes more basic due to losing the Asp side 
chain (see Figure 7-IIA, B). The altered electrostatic distribution of the RIF binding pocket 
may make it less favorable for binding the relatively apolar RMP. 
In the WT RNAP•RMP complex, the H526 (H445 in MTB) residue is involved in 
forming the back wall of the RIF binding cavity and may form a hydrogen bond with 
oxygen atoms of the ansa bridge and/or the Q513 side chain, the latter of which defines 
the RMP binding wall within RRDR cluster I. We determined the crystal structure of the 
H526Y RNAP mutant at 3.6 Å resolution. The structure showed large rearrangements of 
main chain around the RRDR (residues 512-520 and 756-766) due to the H526Y 
substitution, which alters the shape of RMP binding interface (see Figure II-7C, D). Due 
to its very poor affinity for RMP, we could not obtain a crystal structure of the H526Y 
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RNAP•RMP complex. Modeling RMP from the WT RNAP•RMP complex into the H526Y 
mutant RNAP RMP-binding pocket shows that the rearranged RMP binding pocket would 
sterically clash with the rigid plane of the hydrophobic ansa-bridge (from C16 to C23 
positions), particularly at C19 position (see Figure II-7B), therefore effectively preventing 




Figure II-7: Structural basis for inhibition of rifampin by RMPR mutant E. coli 
RNAPs. A) Electrostatic surfaces of the RMP binding pocket of the WT and 
B) D516V mutant RNAPs complexed with RMP (stick models). RNAP 
surfaces are colored with positive (blue), negative (red) and neutral (white) 
electrostatic potentials. Positions of the D516 residue in WT RNAP (A) and 
V516 residue in the mutant (B) are indicated by red circles. C) Comparison 
of the WT and H526Y mutant RNAPs. RNAP structures are depicted as 
ribbon models and were superposed at their RRDRs. D) Steric hindrance of 
RMP binding to the H526Y mutant (left: the WT RNAP•RMP complex; right: 
the H526Y RNAP•RMP complex model). The locations of the clash between 
the ansa bridge of RMP with H526Y are indicated by arrows. E) The RMP 
RIF binding sites of the WT RNAP•RMP has fork loop 2 ordered upon RMP 
binding. F) Fork loop 2 is disordered in the S531L RNAP•RMP complex. Area 
of the RMP naphthalene ring exposure to solvent due to disordering of fork 
loop 2 is indicated by a red arrow. 
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In the WT RNAP•RMP complex, the S531 (S450 in MTB) residue is located in the 
deep cleft of the RMP binding pocket and forms a hydrogen bond with the phenol on C8 
(O2 atom) of the RMP napthalene ring (see Figure II-6A) and the top of the napthalene 
ring is covered by β subunit loops, including fork loop 2 (residues 534-541) 24-26. 
In the crystal structure of S531L RNAP•RMP complex, however, a major difference 
is observed around the β subunit fork loop 2 of which the electron density is weak and 
scattered compared to its counterpart in the WT RNAP•RMP complex. Consequently, 
about half of the RMP naphthalene ring is exposed to solvent (see Figure II-7E, F), 
reducing ~40% of the contact area between RNAP and RMP (386 Å2 and 244 Å2 in the 
WT and S531L mutant, respectively). This alteration dramatically reduces the van der 
Waals interactions resulting in a large loss of binding free energy and is consistent with 
the ~105-fold increase in IC50 of RMP for the S531L mutant compared to WT RNAP. 
Interestingly, fork loop 2 is ordered in the S531L mutant without RMP bound (Figure II-
7E), suggesting that the collision between RMP and the Leu side chain of the S531L 





In order to characterize MTB RNAP, highly pure and active RNAP is required. 
Purification methods of bacterial RNAPs have been widely reported for E. coli, but 
heterologous overexpression of MTB RNAP remained a challenge.14-16 Methodologies 
which used live MTB to produce protein were not a viable option due to safety concerns 
as well as the time needed to grow cultures and isolate protein.14 The efficacy of 
reconstitution methods is low due to improper folding of protein.15 In vivo reconstitution of 
RNAP in the standard E. coli host system represents the most viable option for acquiring 
MTB RNAP. 
Initial attempts of MTB purification using the polycistronic vector pMTBRP series, 
were inefficient due to the disproportionate representation of MTB RNAP subunits which 
were overexpressed. Though the exact cause of this defect was not elucidated several 
attempts to identify the cause were explored. pMTBRP has a single T7 promoter, T7 
RNAP is a highly processive polymerase capable of producing transcripts >15 kilobases, 
more than enough to cover the coding region on pMTBRP.27 Several theories were 
produced to explain why the α-subunit was the only observable subunit overexpressed in 
cell lysates (see Figure II-1). Identification of several rare codons, including the AGG and 
AGA codon (coding for Arg) each of which have an abundance of 3% and 4% can lead 
to pausing events during translation due to a low abundance of the corresponding amino 
acid charged tRNAs.28 Additionally, these sequences, particularly if clustered, are similar 
to the shine-delgarno sequence which can lead to frameshifting along the template and 
eventual premature termination of translation.29 Efforts to remove several of these rare 
codon sites from rpoC were ineffective at recovering overexpression of RpoC protein.  As 
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attempts to introduce additional T7/lacO cis elements upstream of each of the subunits 
was underway a new methodology of overexpression of MTB RNAP was published.17 
This new method uses the Duet expression system. Since the method demonstrated 
production of all subunits efforts to identify the defect with the pMTBRP system were 
ended. 
Banerjee published an optimized method for overexpression of MTB RNAP using 
the Duet expression system.17 In this method two MTB RNAP subunits are introduced 
into each vector, each of which has two independent multiple cloning sites each under 
control of a T7/lac operator. Using this method, the yield of MTB RNAP was reported to 
be ~60 mgs of protein per liter of culture.17 In his system, the decahistidine tag was placed 
on the N-terminus of the α-subunit. However, since we were going to be studying RMPR 
mutations in the β-subunit, we decided to place the decahistidine on the C-terminus of 
the β-subunit (see Figure II-2A). MTB subunits from the pMTBRP expression system 
were subcloned into pET Duet, pAcYc Duet, and pRSF all of which can be co-expressed 
in E. coli because each has a unique origin of replication. Initial trials demonstrated that 
all MTB RNAP subunits could be overexpressed (though the ω-subunit could not be 
distinguished in crude lysates, see Figure II-2B). Purification of MTB RNAP using this 
new system yielded roughly 2-5 mg of protein per liter of culture, significantly less than 
the 60 mg of protein reported by Banerjee. Additionally, purified MTB RNAP appeared to 
lack omega subunit in final preparations. Our observation that the N- and C-termini of the 
β- and β’-subunit coalesce in proximity to where the ω-subunit associates with RNAP 
prompted moving the histidine-tag from the C-terminus of the β-subunit to the N-terminus 
of the α-subunit. 
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In our 2nd generation expression system, we observed that final purification 
preparations have significantly more α-subunit, skewing final protein subunit 
stoichiometry. Despite having a stoichiometry of 2 per molecule of RNAP, the α-subunit 
appeared to be even more highly overexpressed compared to both the β- and β’-subunits. 
This is likely due to the tendency of both of these subunits to form inclusion bodies, 
reducing the amount of subunit available to form viable complex. The uneven prevalence 
of the α-subunits in pre-chromatography sample lead to high occupancy of hexahistidine 
α-subunit on NTA-Ni2+ resin, leading to a significant amount of correctly assembled RNAP 
and excess β- and β’-subunits in the NTA-Ni2+ flow through. This lead to the design of the 
3rd generation expression system as well as a modified purification methodology. 
In our 3rd generation expression system, the histidine-tag was extended from a 
hexahistidine to decahistidine tag and the sigA gene and rpoZ, encoding sigma factor A 
and the ω-subunit were exchanged between their respective plasmids (see Figure II-4A). 
This was done in part to improve binding of the RNAP complex to the Ni2+-affinity resin 
and because the copy number of pRSF is significantly higher than pET and pAcYc. 
Having the ω-subunit on a higher copy plasmid which leads to higher levels of 
overexpressed protein, this resulted in the observation of the ω-subunit in soluble 
fractions of cell lysate (see Figure II-4B).  
Purification methods for procurement of highly pure MTB RNAP holoenzyme were 
expanded to include cation-exchange, affinity, and anion-exchange chromatography 
steps (see Appendix Figure II-A1). In order to remove excess levels of decahistidine-
tagged α-subunit, the first chromatography step used was cation-exchange 
chromatography. RNAP holoenzyme is retained on negatively charged resin, while core 
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RNAP and excess α-subunit flow through the resin (see Appendix Figure II-A2). 
Fractions containing MTB RNAP holoenzyme are then applied to a HisTrap HP, this 
allows for the removal of endogenous E. coli RNAP and is a further purification. RNAP 
yielded from this step of the purification is considerably pure (see Appendix Figure II-
A3). The final polishing step in the purification is anion-exchange chromatography. This 
step, separates MTB RNAP into two peaks, one of which is significantly less active then 
other (see Appendix Figure II-A4). This separation of two distinct complexes may 
indicate that the complex with lesser activity is likely misfolded. Additionally, this complex 
lacks ω-subunit which has been reported to be critical for correct assembly of RNAP in 
mycobacteria as well as other bacterial RNAPs (see Figure II-4B).30 
Initial characterization of the percentage of catalytically competent RNAP (those 
which are able to incorporate NTP into a nascent RNA in an artificial elongation complex) 
showed that a very small percentage of RNAPs were catalytically active. Reports in the 
literature which showed that a zinc-binding domain present in the β’-subunit played a 
critical role in in vitro reconstitution of RNAP complex prompted supplementation of 
growth media with zinc sulfate.22 The drastic increase in catalytically competent RNAP 
complexes purified from cultures supplemented with excess zinc supports the observation 
that the zinc-binding domain likely plays a critical role in RNAP complex assembly (see 
Figure II-5C). Activity of the RMPR MTB RNAPs in the presence of 200 nM RMP show 
that we are not isolating chimeric MTB RNAP complexes containing E. coli RNAP (see 
Appendix Figure II-A6). Though chimeric RNAP formation did not seem to effect MTB 
RNAP, E. coli RNAPs which have a hexahistidine-tag on the C-terminus of the β’-subunit 
contained roughly ~25% β-subunit contamination (see Appendix Figure II-A6). This 
73 
 
would not likely effect IC50 determinations for the E. coli RMPR mutants because 
complexes containing WT β-subunit would be fully inhibited at low concentrations of RMP. 
Characterization of MTB and E. coli RMPR RNAPs susceptibility to challenge by 
RMP showed that point mutations in the RMP cleft are highly effective in reducing the 
potency of RMP (see Figure II-6B). Previous work which aimed to determine the IC50 of 
RMP against both the WT and RMPR MTB and E. coli RNAPs used a single-stranded 
circular DNA template, whereas we are using a plasmid-based template which is more 
representative of physiological conditions.16 A similar trend for the respective mutants in 
both E. coli and MTB can be observed. In both cases the H445Y (H526Y in E. coli) is 
essentially insensitive to RMP, even at 2 mM RMP (see Figure II-6B). The H526Y 
mutation (E. coli numbering) reshapes the RMP binding site and sterically blocks RMP 
binding to RNAP (see Figure II-7C), resulting in insensitivity to RMP. The inhibition by 
high concentrations of RMP that is seen for the E. coli H526Y RNAP is likely due to very 
low affinity RMP binding at a site distinct from the RRDR. 
Using the WT RNAP•RMP complex structure as a template, several studies have 
previously modeled the RNAP structures containing RMPR mutations using molecular 
dynamics simulations or simple amino acid substitutions to postulate the molecular 
mechanisms of RMPR 16, 25-26, 31 The predictions about the D516V RNAP based on the T. 
aquaticus RNAP•RMP complex structure are consistent with the effects observed in the 
D516V RNAP•RMP complex in this work (see Figure II-7B). However, none of the 
previous work identified the RMPR mechanisms of the S531L and H526Y mutants which 
were revealed in our study. 
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Analysis of the structures of S531L RNAP with and without RMP revealed a 
bipartite mechanism resulting in the RMPR phenotype. The two aspects of the S531L 
RMP resistance are: 1) elimination of a key hydrogen bond between the S531 side chain 
and the phenol on C8 of the naphthalene ring; and 2) disordering of fork loop 2 that may 
result from a steric clash between RMP and the Leu side chain at position 531 (see Figure 
II-7F). The disorder of fork loop 2 disrupts RNAP•RMP contacts and also exposes 
hydrophobic segments of RMP to solvent, which is unfavorable for stable RNAP•RMP 
complex formation. In the absence of bound RMP, the S531L mutation did not exhibit any 
gross structural change in the RIF binding site.  The significant structural changes of 
RRDR cluster I found in the H526Y mutant suggest that major modifications of the RMP 
ansa bridge backbone would be required for binding in the significantly altered RIF 
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Chapter II Appendix 
 
• Restriction sites are in bold  
Appendix Table II-A1: Primers used in Chapter II 
Primer Sequence Purpose 
RpoC-MTBRP FOR GCCAACCTGGGAATCAATCTGTCCC Amplify rpoC from pMTBRP for TOPO 
RpoC-MTBRP REV CCTGACGACGGATCGAACTGATCC Amplify rpoC from pMTBRP for TOPO 
rpoA AMP FOR TATACCCATGGTGATCTCACAGCGCCCCACCCTGTCC Amplify rpoA from pMTBRP-NcoI 
rpoA AMP REV GGGGAAGCTTGGCTAAAGCTGTTCGGTTTCGGCGTAGTCCTGCTCGTCG Amplify rpoA from pMTBRP-HindIII 
rpoB AMP FOR GAACCCCATGGCAGATTCCCGCCAGAGCAAAACAGCCGC Amplify rpoB from pMTBRP-NcoI 
rpoB AMP REV GATCGGATCCTTAATGGTGATGGTGATGGTGATGGTGATGGTGCG 
CAAGATCCTCGACAC 
Amplify rpoB from pMTBRP-BamHI  
rpoC AMP FOR GGGAGTCATATGCTCGACGTCAACTTCTTCGATGAACTCC Amplify rpoC from pMTBRP-NdeI 
rpoC AMP REV CGTTATTTGAGGATATCCTAGCGGTAGTCGCTGTAGCCG Amplify rpoC from pMTBRP-EcoRV 
rpoZ AMP FOR ATTACATATGAGTATCTCGCAGTCCGACGCG Amplify rpoZ from pMTBRP-NdeI 
rpoZ AMP REV GAGTGGTACCGCTACTCGCCCTCGGTGTGC Amplify rpoZ from pMTBRP-KpnI 
SigA AMP FOR GAAGGGGTGTCCATGGCAGCGACCAAAGCAAGCACGGCGACCGATGAGCC Amplify SigA from gDNA for pRSF-NcoI 
SigA AMP REV GCCTCGGCGGCAATTGTCAGTCCAGGTAGTCGCGCAGGACCTGTGAGCGG Amplify SigA from gDNA for pRSF-MfeI 
rpoA FOR NTHis GAGAGGATCCTATGCTGATCTCACAGCGCCCCACCCTGTCC Amplify rpoA for pAcYc-BamHI  
rpoB AMP 2 FOR ATACCATGGTGTTGGCAGATTCCCGCCAGAGCAAAACAGC Amplify rpoB without His-tag-NcoI 
rpoB AMP 2 REV CGGGATCCTTACGCAAGATCCTCGACACTTGCGGATTCGT Amplify rpoB without His-tag-BamHI 
rpoA 1-229 AMP 
REV 
GATCTCAAGCTTCTAGGCCTCGACGTTGAGTTCCCGTGCC Amplify truncated rpoA 1-229-HindIII 
rpoA AMP 3 REV GGCCGGTACCTTCTAAAGCTGTTCGGTTTCGGCG Amplify rpoA with no His tag for pAcYc-KpnI 
rpoA N10his FOR TATACCATGGGCAGCAGCCATCACCATCACCATCACCATCACCATC 
ACAGCCAGGATCCTATGCTGATCT 
Amplify rpoA with N-terminal his10x - NcoI 
rpoZ NcoI AMP 
FOR 
CATTACCATGGGTATCTCGCAGTCCGACGCG Amplify rpoZ with NcoI for pRSF 
rpoZ MfeI AMP 
REV 
GAGTCAATTGGCTACTCGCCCTCGGTGTGC Amplify rpoZ with MfeI for pRSF 
SigA NdeI AMP 
FOR 
GATCCATATGGCAGCGACCAAAGCAAGCACGG Amplify SigA with NdeI for pAcYc 















Appendix Figure II-A2: Purification of MTB RNAP with cation-exchange chromatography. 
A) Representative chromatogram of MTB RNAP purification using a 
6mL Source 15S column (GE Healthcare). B) Close up of peaks eluted 
from A. C) SDS-PAGE MTB RNAP purification using the Source 15S 
column including pre-injection, Source 15S flow through, and eluted 





Appendix Figure II-A3: Purification of MTB RNAP with immobilized-metal affinity 
chromatography. A) Representative chromatogram of MTB 
Purification using a 1mL HisTrap HP column (GE Healthcare). B) 
SDS-PAGE of MTB RNAP purification using the HisTrap HP column 







Appendix Figure II-A4: Purification of MTB RNAP with anion-exchange chromatography. 
A) Representative chromatogram of MTB RNAP purification using a 
6mL Source 15Q column (GE Healthcare). B) Close up of peaks eluted 
from A. C) SDS-PAGE MTB RNAP purification using the Source 15Q 
column including pre-injection, Source 15Q flow through, and eluted 








Appendix Figure II-A5: Determination of percent of contaminating endogenous WT E. coli 
RNAP in the RNAP purifications. A) Contamination in E. coli RMPR 
and B) MTB RMPR RNAP preparations. Essentially no endogenous 






Appendix Figure II-A6: Rifampin IC50 curves for WT and RMPR E. coli and MTB RNAPs. A) 
E. coli RNAPs (WT and RIFR mutants) and (B) MTB RNAP (WT and 
RIFR mutants). All of the average data points (•) were plotted. The 
average data were fit by nonlinear regression, with upper and lower 
limits set to 100 and 0 respectively, to determine their IC50 values. In 
the WT RNAP plots, the values at log = -10, annotated with a single 
asterisk, are the DMSO controls. The dashed line indicates the limits of 
detection, either from enzyme concentration limitations needed for 







In vitro Characterization of Rifampin Resistant M. tuberculosis RNA polymerases 
Development of resistance to antibiotics usually comes at some cost to the 
organism’s fitness 1-2. A significant fitness defect, coupled with prolonged exposure to 
antibiotics, creates an environment where selective pressure to compensate for fitness 
defects can lead to the development of secondary mutations. There have been extensive 
studies correlating the prevalence of RMPR mutations in MTB clinical isolates with the 
fitness costs of rifamycin-resistance 3-6. Most of these studies employed either 
competition assays or growth rate measurements to determine if a resistance mutation 
causes a fitness defect 7. Though many of the studies have tried to identify correlations 
between fitness and genotype, differences in genetic background and artificial growth 
conditions may convolute how fitness is presented. Additionally, pleiotropic effects from 
drug resistance mutations can further complicate interpretation of direct effects from a 
particular mutation. In contrast, the intrinsic changes in enzyme function in vitro can be 
interpreted as a direct effect of a particular mutation. 
Laboratory-evolved strains carrying the same RMPR point mutations have been 
observed to exhibit varying fitness defects. Interestingly, strains carrying the βS450L 
mutation tend to exhibit the least fitness defect when compared to other RMPR mutants 
in competition studies. The minimal observed fitness defect for this particular mutant was 
used as rationale for explaining its prevalence in clinical isolates 3. However, a number of 
clinical isolates containing the βS450L mutation were observed to have varying fitness
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 defects despite sharing the same RMP resistance allele. This led to the discovery of 
secondary mutations, predominantly at the interface of the α- and β’-subunits of RNAP, a 
majority of which are found in the double-psi beta-barrel (DPBB) domain of the β’-subunit, 
the distal end of which contributes to the catalytic site of RNAP and includes the 
magnesium-coordinating motif, DFDGD (see Figure I-5). We refer to these secondary 
mutations as “compensatory mutations” for their ability to ameliorate/compensate for the 
fitness defects of the primary RMPR mutants. The presence of these compensatory 
mutations is overwhelmingly, but not exclusively associated with the βS450L RMPR 
mutation (75%), approximately 9% of the compensatory mutations were observed in the 
rpoA or α-subunit 7-8. The β’V483G and β’F452L mutations are the most prevalent 
mutations associated with the βS450L mutant and have been observed in all of the 
studies mentioned above, suggesting that they arose by convergent evolution and are 
physiologically relevant to the organism 3. 
There is an incomplete understanding regarding the disproportionate 
representation of particular RMPR mutations in clinical isolates despite the similar 
efficacies of these mutations to decrease the susceptibility of RNAP to RMP 9. Our study 
provides a molecular foundation for the enrichment of the βS450L mutant in clinical 
isolates and elucidates fitness defects associated with this mutant which likely drive the 
pressure to develop compensatory mutations. Three MTB trans-acting transcription 
factors, CarD, NusA, and NusG, were also studied to determine the extent of alteration 
of the intrinsic properties of each RMPR mutant in physiologically relevant contexts. 
Several studies of RMPR E. coli have shown that mutations in the RRDR have differential 
effects on transcription initiation, elongation, and termination 10-13; however, these 
89 
 
mutants have usually been selected from phenotypic screens of laboratory evolved RMPR 
mutants and differ from those observed in clinical settings. Until now these effects have 
not been biochemically characterized in clinically relevant MTB RMPR RNAPs.  These 
studies provide insight into aspects of transcription which are critical to the MTB viability. 
Materials and Methods 
Plasmid and DNA Manipulation 
Plasmid pMt-rrnA3 contains the MTB rrnA3 promoter region -66 to +351. DNA was 
amplified from H37Rv genomic DNA (+1468189 to +1468605) and subcloned into 
pTZ18U using PciI and EcoRI restriction sites using primers Mt rrnA3 -66 AMP FOR and 
Mt rrnA3 +351 AMP REV (see Appendix Figure III-A1 and Appendix Table III-A1 for all 
primers). pMt-rrnA3-synB was produced by insertion of the synB terminator derived from 
synthetic oligonucleotides (IDT Technologies) with flanking XbaI restriction sites (see 
Appendix Table III-A1 for all plasmids). pMt-rrnA3 derivative, pEC19, was produced by 
mutagenesis of both adenosines A10 and A11 (relative to the rrnA3 TSS) to thymine using 
rrnA3 EC19 FOR and rrnA3 EC19 REV. pEC26-Tuf was generated by digestion of pMt-
rrnA3 with PciI and MscI to remove the MTB rrnA3 promoter. The E. coli consensus 
promoter which lacks any cytosine until the +26 position, relative to the transcription start 
site, was subcloned using synthetic oligonucleotides. The MTB tuf and metK terminators 
were subcloned into pEC26 using synthetic oligonucleotides containing the terminator 
sequences with flanking XhoI restriction sites. Plasmids used for promoter studies were 
purified using a Qiagen Miniprep kit. PCR amplified DNA fragments were generated from 
pEC19 (elongation studies) and pEC26-Tuf or pEC26-metK (termination studies) using 
primers EC19 AMP FOR and EC AMP REV for the elongation studies template and EC26 
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AMP FOR and EC AMP REV for the termination studies. PCR products were purified on 
a 2% agarose gel and extracted with Qiagen gel extraction kit. Plasmid DNA and PCR 
fragments were then further purified by phenol-chloroform extraction followed by ethanol 
precipitation. DNA was stored in water at -20°C. 
Expression constructs for MTB CarD (Rv3583c), NusA (Rv2841c), and NusG 
(Rv0639) were produced similarly. Each gene was amplified from H37Rv genomic DNA 
using primers in Appendix Table III-A1. All genes were subcloned into a modified 
pET19b construct containing a N-terminal decahistidine tag followed by the Precission 
Protease recognition cleavage site LEVLFQ/GP (pET19bpps). CarD and NusA were 
subcloned into the pET19bpps vector using NdeI and BamHI restriction sites. NusG was 
subcloned into pET19bpps using the NdeI and XhoI restriction sites (see Appendix Table 
III-A2). 
Protein Purification 
MTB RNAP was prepared as previously reported 9. CarD was prepared as follows. 
BL21(DE3) E. coli containing pET19bpps-CarD were grown to an OD600 of 0.8. Protein 
expression was induced by addition of 1mM IPTG. Cells were incubated at 28°C for 4 
hours prior to harvesting via centrifugation. Cells were lysed via sonication in 20 mM Tris-
HCl (pH 8.0), 300 mM NaCl, 5% glycerol, 5 mM β-ME (β-mercaptoethanol), 1 mM PMSF 
and 1X Roche cOmplete ULTRA protease cocktail), 200U DNaseI, and 1 mg/mL 
lysozyme. Clarified lysate was passed through a 0.22 um filter and applied to a HisTrap 
HP column (GE Healthcare). CarD was eluted over linear gradient to 500 mM imidazole. 
Fractions containing decahistadine-tagged CarD were collected and Precission Protease 
(GE Healthcare) was added. CarD was dialyzed overnight at 4°C in 10 mM Tris-HCl (pH 
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8.0), 500 mM NaCl, 0.1 mM EDTA, 5% glycerol, 5 mM β-ME. CarD was then passed 
through 1 mL of GST-agarose to remove Precission Protease and concentrated prior to 
application to a HiPrep Sephacryl S-200 HR column (GE Healthcare) run in 20 mM Tris-
HCl (pH 8.0), 200 mM NaCl, 0.1 mM EDTA, 5% glycerol, and 1 mM DTT. Purified CarD 
was stored at -80°C (see Appendix Figure III-A2). 
NusA and NusG were prepared identically. E. coli BL21 (DE3) cells containing 
either pET19bpps-NusA or pET19bpps-NusG were grown to an OD600 of 0.4 and induced 
by addition of 0.5 mM IPTG. Cells were incubated overnight at 16°C. Cells were lysed via 
sonication in 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 5mM imidazole, 5% glycerol, 5 mM 
β-ME, 0.1% Triton X-100, 1 mM PMSF and 1X Roche cOmplete ULTRA protease 
cocktail), 200U DNaseI, and 1mg/mL lysozyme buffer. Clarified lysate was passed 
through a 0.22µm filter and then applied to a HisTrap HP column and proteins were eluted 
by a linear gradient to 500mM imidazole. Fractions containing either Nus protein were 
collected and Precission Protease was added. Proteins were dialyzed into 10 mM Tris-
HCl (pH 8.0), 50 mM NaCl, 5 mM β-ME, 5% glycerol, 0.1 mM EDTA and passed through 
1 mL of GST-agarose before application to a 6 mL Source 15Q column equilibrated with 
TGEB (10 mM Tris-HCl (pH 8.0), 5% glycerol, 0.1 mM EDTA, 5 mM β-mercaptoethanol) with 50 
mM NaCl and eluted over a linear gradient to 1 M NaCl. Fractions containing Nus proteins 
were collected and dialyzed into 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.1 mM EDTA, 






Determination Open-promoter Complex Half-life 
Open-promoter complex half-life was determined by single-round transcription. 
Supercoiled plasmid template containing -66 to +350 of the transcription start site of the 
MTB rrnA3 promoter followed by the synB terminator was used for this assay. MTB RNAP 
(30 nM) was pre-incubated with pMt-rrnA3-SynB (10 ng/μL) for 30 minutes at 37°C to 
form the open-complex in 40mM Tris-HCl (pH 8.0), 10 mM MgCl2, 30 mM KCl, 1 mM DTT, 
0.1 mM EDTA, and 25 µg/mL BSA. When present, CarD was added to a final 
concentration of 2 µM and incubated for an additional 5 minutes. Heparin was then added 
to 50 µg/mL and aliquots taken at various time points were added to the NTP mixture (1 
mM GTP, 200 µM ATP, 200 µM UTP, 10 µM CTP, 0.15 µCi/uL [α32P]CTP final 
concentration). Reactions were allowed to continue for 15 minutes before addition of 2X 
RNA loading buffer (95% formamide, 0.02% SDS, 0.01% bromophenol blue, 0.005% 
xylene cyanol, 0.5 mM EDTA). Reactions were resolved via 6% acrylamide, 8 M urea 
PAGE. Gels were imaged and bands quantified by phosphorimaging (Molecular 
Dynamics, ImageQuant software). The fraction of complex at each time point was 
normalized to the zero time point and fitted to a linear plot. The half-life was determined 
by calculating the time at which half of the remaining complex was present. All reactions 
were conducted in triplicate with the errors representing the standard deviation of the 







Determination of elongation rate 
Elongation rate was determined by a single-round transcription assay on a linear 
template. MTB RNAP (120 nM) was pre-incubated with linear DNA (30 nM), EC19, in 40 
mM Tris-HCl (pH 8.0), 10 mM MgCl2, 10 mM KCl, 1 mM DTT, 0.1 mM EDTA, and 25 
µg/mL BSA for 15 minutes at 37°C. Stalled-elongation complex was formed by incubating 
10 µM GTP, 10 µM UTP, 2 µM CTP, and 0.3 µCi/µL [α32P] CTP for 10 minutes. 
Transcription was resumed by adjusting the all NTPs to 100 µM and addition of 50 µg/mL 
heparin. Aliquots were removed at the time points denoted in the figures and stopped by 
addition of 2X RNA loading buffer.  Reactions were resolved via 8% acrylamide, 8 M urea 
PAGE and processed as mentioned above. Elongation rates were determined by 
quantifying the density of run-off product over time which was fit to a standard Boltzmann 
sigmoidal curve. Average elongation rates were determined as the point at which 50% of 
runoff product is formed and is presented in nucleotides per second. All experiments were 
conducted in triplicate. 
Determination of termination efficiency 
Termination efficiencies were determined by single-round transcription assays on 
linear templates. MTB terminators tuf and metK  were identified by genomic profiling of 
MTB intrinsic terminators 14. MTB RNAP (50 nM) was pre-incubated with linear DNA (25 
nM), EC26-metK or EC26-Tuf, in 40 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 10 mM KCl, 1 
mM DTT, 0.1 mM EDTA, and 25 µg/mL BSA for 15 minutes at 37°C. Stalled elongation 
complexes were formed by incubating 10 µM GTP, 10 µM ATP, 2 µM UTP, and 0.1 µCi/µL 
[α32P]UTP for 10 minutes. When used, NusA and NusG were added to 1 µM and allowed 
to incubate for 10 minutes. Transcription was restarted by addition of 50 µg/mL heparin 
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and adjusting each NTP concentration to 200 µM. Reactions were allowed to continue for 
30 minutes before 2X RNA loading buffer was added. Reactions were resolved on 6% 
acrylamide, 8M urea PAGE and processed as mentioned above. Termination efficiencies 
were calculated by dividing the density of terminated products by the sum of the 
terminated and runoff products in each lane. 
Primer extension Assays 
Determination of the concentration of active RNAP and percent of RNA hydrolysis 
was conducted using a DNA•RNA scaffold that mimics the transcription elongation 
complex. 15  First, an 8 nucleotide RNA (IDT technologies) was labeled at the 5’ end with 
[γP32] GTP (Perkin Elmer) using T4 polynucleotide kinase (New England Biolabs). The 
T4 polynucleotide kinase was then heat inactivated. The DNA•RNA heteroduplex 
scaffolds were prepared by mixing equimolar amounts of template DNA26 (5’-
CTGAAATCGACATCGCCGCTCAACAT-3’) and 5’-labeled RNA8 (5’-GCGGCGAU-3’), 
heating to 85 °C for 10 min, followed by slow cooling to room temperature. The elongation 
complex was formed by mixing equimolar RNAP with the DNA•RNA heteroduplex scaffold 
(500 nM) in reaction buffer at 28 °C for 10 min. The reaction consisted of 40 mM Tris-HCl 
(pH 7.9), 40 mM potassium glutamate, 0.1 mM EDTA, 10 mM MgCl2, 25 µg/mL BSA, 1 
mM DTT; both reactions contained 15 mU of inorganic pyrophosphatase (New England 
Biolabs). The RNA extension reaction was conducted for 10 min after adding the next 
incoming GTP (400 μM final concentration) to the elongation complex. RNA extension 
was stopped by adding an equal volume of 2x RNA loading buffer. RNAs were resolved 





RMPR mutant RNAPs form unstable open-promoter complexes which are stabilized by 
compensatory mutations in the β’-subunit.  
Single-round transcription assays performed on supercoiled plasmid DNA 
template containing the MTB ribosomal RNA promoter (rrnA3) upstream of the synB 
terminator 16 were used to determine open-complex half-lives in the presence and 
absence of CarD (see Figure III-1, Appendix Figure III-A3), a transcriptional regulator 
which is known to stabilize the rrnA3 open-promoter complex. The open-promoter 
complex half-life (t1/2= 1.5 min) for the wild-type (WT) MTB RNAP determined in the 
absence of CarD under these conditions is consistent with previous reports in the 
literature (t1/2 = 2 min) 17. All single RMPR mutations reduced the stability of the RNAP 
open-promoter complexes, having half-lives ~50% of that for the WT. The compensatory 
mutations, β’F452L and β’V483G, provide stabilizing effects (20-30% longer half-life) on 
the WT open-promoter complex. These compensatory mutations also mitigated the defect 
in open-promoter complex stability for the βS450L mutant. Open-promoter complex half-
lives were not evaluated for the βD435V and β445Y mutants with compensatory 
mutations because these mutants are not observed in clinical isolates. Similar to in vivo 
observations, the β’F452L mutation partially recovered this defect (from 50% to 75% of 
WT) and the β’V483G mutation fully recovered the stability defect, bringing the open-
complex half-life for the βS450Lβ’V483G double mutant essentially equal to that of the 





Figure III-1: Open-promoter complex studies with MTB RNAP in the presence and 
absence of CarD. A) Bar graph of open-promoter complex half-lives at the 
MTB rrnA3 promoter in the presence and absence of transcription factor 
CarD. (Note: Promoter half-life times are in Log2 scale). B) Table of open-
promoter complex half-lives of MTB RNAP variants in presence and 






In the presence of CarD the WT open-promoter complex was stabilized roughly 5-
fold (see Figure III-1B and Appendix Figure III-A3). CarD also stabilized all RNAP 
mutant half-lives 5- to 8-fold, with the exception of the βH445Y mutant which exhibited 
only a 2.4-fold increase in half-life. A similar trend in open-complex half-life across the 
RNAP variants is observed in the presence of CarD. Whether CarD is present or not, all 
RNAPs containing a compensatory mutation in the β’-subunit have a half-life greater than 
that observed for WT. 
Compensatory mutations in the β’-subunit mitigate the defect in elongation rate for the 
βS450L RMPR mutant.   
Elongation rates for WT and each of the MTB RNAP mutants were determined 
using single-round transcription assays on a linear template containing the rrnA3 
promoter (see Figure III-2, Appendix Figure III-A4). Run-off transcripts from this 
template produce a 398 nucleotide RNA. The template was modified by substitution of 
A10 and A11 each with T to allow for formation of a stalled elongation complex at the +19 
position (EC19). βD435V and βH445Y RMPR RNAPs have greater elongation rates 
relative to WT, whereas the βS450L mutant has a significantly slower elongation rate (). 
Again, the presence of a compensatory mutation in the β’-subunit was able to 
substantially mitigate this defect (see Figure III-2B). Each compensatory mutation on its 
own resulted in an increase in elongation rate relative to WT. It is noteworthy that there 
is a lack of significant pause sites along the span on the transcribed sequence 
downstream of the stalled +19 site. This allows the observed elongation rates to be 
attributed to processivity (phosphodiester bond formation) and not confounded by time 




Figure III-2: Elongation Rate of WT and RMPR MTB RNAPs. A) Plots used to determine 
the elongation rate for each of the RNAPs in this study. Density of runoff 
transcript was plotted against time. The time at which 50% of elongating 
RNAPs reach runoff length was divided by the length of the transcribed 
region to determine the average elongation rate. B) Summary of MTB 






The βS450L mutation improves termination efficiency, while the βD435V and βH445Y 
mutations cause defective intrinsic termination at the tuf and metK terminators.   
Termination efficiency was determined by single-round transcription on a linear 
template containing the tuf or the metK terminator downstream of a strong E. coli 
consensus promoter 16. RMPR mutant RNAPs had varying termination efficiencies (see 
Figure III-3) which inversely correlated with elongation rates (see Figure III-6B). For both 
the metK and tuf terminators, there are two adjacent termination sites (consistent with the 
reported termination pattern for the tuf terminator 16), the bands for both of which were 
included in the calculation of termination efficiency (see Figure III-3A). The βD425V and 
βH445Y RMPR were less able than WT to terminate at either terminator. RNAPs 
containing the βS450L mutation overall were clearly the most efficient at intrinsic 
termination. The presence of either the β’F452L or β’V483G mutation decreased the 
termination efficiency of the WT RNAPs. However, both double mutants (βS450L/β’F452L 
and βS450L/β’V483G) retained higher termination efficiencies than WT, albeit lower than 




Figure III-3: Termination studies at the tuf and metK terminators with all MTB 
RNAPs included in this study in the presence and absence of NusA 
and NusG. A) Phosphorimage gels used to calculate termination 




Trans-acting termination factors, NusA and NusG (Rv0639), were also included in 
termination assays. NusA stimulates termination 19. Rv0639 was annotated as the NusG 
homolog in MTB; however, characterization of the protein indicates it diverges from the 
canonical function observed for NusG in E. coli by stimulating termination in MTB 16, 20. 
MTB rv0639/NusG had varying effects on termination depending on the terminator and 
RNAP mutant. At the tuf terminator, the RNAPs containing no RMPR mutations exhibited 
the strongest increases in termination efficiencies upon addition of NusG relative to other 
RNAPs. This was not the case at the metK terminator. At the metK terminator, RNAPs 
containing the βS450L mutation had the greatest, albeit modest relative to the tuf 
terminator, increases in termination efficiencies relative to no NusG, although this 
increase was less than that for WT with the tuf terminator. The βS450L mutant was highly 
efficient at termination in the absence of Nus factors. NusA, which has been shown to 
increase termination efficiency in vitro for E. coli 21-22, had essentially no effect on 
termination efficiencies. NusG stimulates pausing along the template in the elongation 
assay (see Appendix Figure III-A5). 
Compensatory mutations in the DPBB enhance RNA primer hydrolysis.  
Single nucleotide hydrolysis of, and incorporation into an RNA8:DNA26 
heteroduplex scaffold were monitored by denaturing PAGE (see Figure III-4A) 15. We 
observed varying degrees (all much smaller than incorporation) of hydrolysis of the 3’ 
UMP of the RNA8 oligonucleotide to a 7-mer product (see Figure III-4B-C). This likely 
happened during the 10-minute preincubation prior to the addition of GTP. RNAP double 
mutants with the βS450L mutation and a compensatory mutation in the β’-subunit had 




Figure III-4: Percent hydrolysis of WT and RMPR MTB RNAPs. A) RNA•DNA scaffold 
used in this study. B) Radiograph showing primer extension and hydrolysis 





(both with and without the βS450L mutation) having the greatest propensity for hydrolysis. 
The βD435V and βH445Y RMPR mutants displayed lower levels of hydrolysis, while the 
βS450L mutant displayed a similar proclivity for hydrolysis to that of the WT (see Figure 
III-6C). Upon addition of GTP, the RNA8 is extended to the 9-mer. (Any hydrolysis of the 
9-mer back to the 8-mer would be immediately corrected by addition of another G due to 
the excess of GTP (800-fold) present.) The percentage of active (e.g., catalytically 
competent) complex in a given preparation of RNAP was determined as the sum of the 
extension to the 9-mer and hydrolysis to the 7-mer RNA. MTB RNAPs used in this study 
had activities ranging from 45-77% (see Figure III-6C, Appendix Table III-A3). 
Discussion 
Rifampin resistant (RMPR) mutations in the rifamycin-resistance determining 
region (RRDR) have been observed to affect open-promoter complex (RPo) stability in 
the E. coli RNAP 11. We find that RMPR mutations in the β-subunit of MTB RNAP 
(βD435V, βH445Y, and βS450L) all share similar reductions in RPo complex stabilities 
relative to WT RNAP. CarD, a transcription factor that significantly (5-8-fold) increases 
RPo stability for all MTB RNAPs studied, had minimal effects on the trends observed for 
the WT and RMPR mutants in the absence of CarD, with the exception of the βH445Y 
mutant which had a lower fold change in promoter half-life (see Figure III-1). We have 
previously shown that the βH445Y MTB RNAP exhibits a significantly altered RMP 
binding pocket conformation 9 and the greatest reduction in RPo stability relative to WT. 
This may reduce the ability of CarD to fully stabilize the RPo complex for this mutant. 
The RMPR mutations in the β-subunit are adjacent to Fork Loop 2 (FL2) which has 
been observed to adopt multiple conformations, one where it interacts with the leading 
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edge of the transcription bubble and others where it makes contacts with the bridge helix 
23-24. In the E. coli RNAP crystal structures with RMP, FL2 of the βS531L (βS450L in MTB 
numbering) mutant was disordered, reducing contacts with RMP (likely the source of the 
mutant RNAP’s ~10,000-fold reduction in affinity for RMP). A disordered FL2 was not 
observed in the WT E. coli RMP complex structure 9. This structural difference suggests 
that a defect in the conformational stability of FL2 is likely a contributor to the 
destabilization of the RPo observed in the RMPR mutants. 
Interestingly both compensatory mutations studied, β’F452L and β’V483G, had a 
stabilizing effect on RPo half-life for the βS450L mutant. The degree of stabilization for 
the β’F452 and β’V483G mutations partially and fully complemented the defect observed 
for the βS450L mutation; consistent with growth rate and fitness determination 
measurements of M. smegmatis expressing recombinant MTB rpoB-rpoC alleles with 
these mutations 18. The switch region of RNAP aids in the closure of the RNAP clamp on 
DNA and forms a complex network which directly interacts with the template strand (see 
Figure III-5) 25-26. Mutations in the switch region have been shown to negatively affect 
open-promoter complex stability via weakening the strength of the RNAP clamp on the 
DNA 26-29. Switch 3 makes extensive contacts with the alpha-helical region above the 
DPBB where the compensatory mutations studied here reside and Switch 2 feeds into β-
sheet 1 of the β-barrel. Compensatory mutations in the DPBB domain may induce 
conformational changes in the switch region to rectify defects in RPo stability caused by 
the RMPR mutations in the β-subunit through interaction with the template strand (see 




Figure III-5: Structure of Mycobacterium smegmatis RNAP with full transcription 
bubble (PDB: 5VI5) 30. A) Highlighted structural motifs which contribute to 
effects observed on transcription. B) Perspective of RNA•DNA 
heteroduplex region from the perspective of the compensatory mutations in 
the DPBB (left panel) and the RifR mutations (right panel).  
 
Surprisingly, despite being the most prevalent of the RMPR mutants present in 
isolates, the βS450L mutant showed the greatest defect in its elongation rate, whereas  
the βD435V and βH445Y RMPR mutants increased the rate of elongation relative to WT 
(see Figure III-2).  The variability in rate of elongation among the RMPR mutants is 
curious, but not unprecedented. Mutations in this region of the β-subunit have been 
shown to have varying effects on elongation rate 10. A laboratory-evolved RMPR mutation 
in the E. coli RNAP, βI572N, resulted in an attenuated elongation rate while mutation of 
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the same amino acid to a threonine had no effect on elongation rate 10. There are other 
instances in which mutations in this region of the β-subunit effect elongation rate 
(increases and decreases relative to WT) 10, 31-35.  The βS450L mutation is the closest of 
the three RMPR mutations to FL2, which does adopt multiple conformations, suggesting 
it plays a role in the elongation 23-24, 36. Additionally, FL2 stimulates elongation rate via 
sequestration of incoming NTP and promotion of phosphodiester bond formation. It has 
been suggested this occurs by allosterically influencing fork loop1 (FL1) 37. FL1 makes 
up part of the active site and has a glutamate which may coordinate NTPs in the i +1 site 
37. The βS450L mutation may indirectly affect the function of FL1 in the sequestration of 
NTP substrate, attenuating the elongation rate. 
Conformational changes in the fork domain (fork loop 1 and fork loop 2) are thought 
to promote RNAP clamp closure around the RNA•DNA heteroduplex, helping to maintain 
elongation complex stability 26. The RMPR mutations in the fork domain have been shown 
to cause slippage along homopolymeric template DNA with E. coli and S. cerevisiae 
RNAP 10, 38-39. It is thought that this occurs from weakening of the clamp causing 
spontaneous melting of the heteroduplex region 10. The RMPR mutations in this study are 
clustered around this heteroduplex region on the RNA side of the RNA•DNA heteroduplex 
(see Figure III-5). Mutations in this pocket affect the steric and surface 
(polarity/electrostatic) parameters of the RNA exit channel and have the potential for 
either weakening or strengthening interactions between the residues within the rifamycin-
binding cleft and the extending nascent RNA 9. As one consequence, mutations in the 
RMP cleft could have signification effects on translocation of the RNAP and elongation 
rate. Given the proximity of the RMPR mutations to the DFDGD motif, an alternative 
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explanation for these effects is (perhaps subtle) alteration of the catalytic magnesium 
position (see Figure I-5). 
“Backtracking” is a process where the RNA•DNA hybrid region translocates in the 
reverse direction, shifting the 3’- end of the RNA into the i site and re-forming the post-
incorporation/pre-translocation state. This most often happens in the process of “proof-
reading” 40-41. Weakened RNA•DNA hybrid regions are associated with an increased 
ability for the heteroduplex to backtrack 42-43, preventing incorporation of any new NTP 
and rendering the 3’ nucleotide susceptible to hydrolysis. We observed that the mutations 
studied have varying effects on the hydrolysis of the 3’ nucleotide of the RNA8 (see 
Figure III-4). Consistent with observations for RNAPs which are deficient in backtracking 
(faster RNAPs are less prone to backtracking), diminished exonuclease activity was 
observed for the βD435V and βH445Y mutants 42. In contrast, the βS450L/β’V483G 
mutation dramatically increases hydrolysis of 3’-UMP from RNA8 while also decreasing 
the elongation rate. The RMPR mutations (on the RNA side of the RNA•DNA hybrid) may 
affect the RNA•DNA hybrid such that forward translocation is increased, resulting in 
increased elongation rates and reduced backtracking and hydrolysis. While the 
compensatory mutations (which occur on the DNA side of the heteroduplex) may have 
similar effects on the RNA•DNA hybrid, they could also perturb the region around the 
catalytic magnesium, where changes in spatial environment have been shown enhance 
3’-5’ exonuclease activity 43. 
RNAPs which do not efficiently recognize termination signals will continue 
transcribing neighboring genes. Screening performed to identify altered termination 




Figure III-6:  Concluding observations from kinetic studies of MTB RNAPs. A) 
Similarity between Open-promoter complex and Growth as well as 
elongation rate and competitive fitness observed for the clinically relevant 
genotypes (*Competitive fitness and growth were determined in Song et 
al. 18).  B) Inverse correlation between elongation rate and termination 
efficiency observed for the MTB RNAP variants in this study. 
 
12. Our observations indicate that mutant RNAPs carrying the βS450L are not just more 
efficient at intrinsic termination than the other RMPR mutants studied but are also more 
efficient than the WT RNAP. Although the presence of a single compensatory mutation 
yields a slight decrease in termination efficiency, the double mutants maintain termination 
efficiencies which are still greater than WT at both the tuf and metK terminators (see 
Figure III-3).  
Interestingly, as noted above for RPo stability, the relative elongation rates for the 
mutants containing the S450L in this study also mirror the relative competitive fitness 
observed in M. smegmatis (see Figure III-6A).18 Production of rRNA in vivo is coupled to 
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growth rate and organism fitness.44 It is possible that slow-growing bacteria such as M. 
tuberculosis, which has an elongation  rate 15 times slower than that of E. coli, could 
present fitness defects that are reflective of reduced production of rRNA We also 
observed that elongation rate and termination efficiency are inversely correlated (see 
Figure III-6B), which is consistent with previous reports 16, 33. Our results suggest that 
this aspect of transcription may be the driving factor for initial RMPR mutant selection. 
While many factors contribute to the fitness of the organism, these intrinsic properties of 
the RMPR mutants will likely have a major impact on fitness. 
Trans-acting Nus factors A and G from MTB were also tested to determine the 
extent to which they alter termination efficiencies (see Figure III-4). As previously 
reported, MTB NusA had no effect on the termination efficiencies, despite observed 
effects in an E. coli-based transcription system. However, MTB NusG did increase the 
termination efficiencies for many of the mutant RNAPs tested, though not all. It had limited 
effects on termination when termination efficiencies were very low or very high. For low 
termination efficiency RNAPs, the elongation rate may be too fast for NusG to enhance 
termination and the incremental effect of NusG may be masked in high termination 
efficiency RNAPs. 
Our study explored the molecular basis for the fitness defects of certain RMPR 
mutants observed in MTB clinical isolates. We found that there are distinct mechanistic 
and kinetic differences for each RMPR mutant. These studies provide insight into the 
mechanistic framework for the evolution of secondary, compensatory mutations observed 
in the β’-subunit of RNA polymerase. We conclude that a critical factor is the balance 
between elongation rate and termination efficiency and that this likely explains the 
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prevalence of the βS450L mutation and contributes to the presence of compensatory 
mutations. Another factor which seems to drive secondary mutations in the β’-subunit is 
their effect on RPo stability. Further studies which probe the structural consequences of 
the RMPR mutant fitness defect compensation by compensatory mutations in the β’-
subunit are needed to confirm the exact mechanism of action of these mutations. 
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Chapter III Appendix 
Primer Sequence  Purpose 
Mt rrnA3 -66 
AMP FOR 
GATCACATGTATGGATATCTATGGATGACCGAACCTGG Amplification of rrnAP3 -66 from TSS 
Mt rrnA3 +351 
AMP REV 


























Consensus E. coli promoter for 
termination studies 
EC19 AMP FOR ATGGATATCTATGGATGACCGAACCTGG Amplification of DNA template 
EC26 AMP FOR TTGTTGTTAACTCTTGACAAAAGTGTTAAAAGCGG Amplification of DNA template 
EC AMP REV GCCTGCAGGTCGACTCTAGAGG Amplification of DNA template 
rrnA3 EC19 FOR GACTGGCAGGGTTGCCCCGTTGCGGGC0GG Stalled Elongation Mutagenesis 
rrnA3 EC19 REV CCGCCCGCAACGGGGCAACCCTGCCAGTC Stalled Elongation Mutagenesis 
CarD AMP FOR GGGAATTCCATATGATTTTCAAGGTCGGAGACACCGTTGTC Amplification of CarD from gDNA† 
CarD AMP REV GATCCCGGATCCTCAAGACGCGGCGGCTAAAACCTCGTCAAG Amplification of CarD from gDNA† 
NusA AMP FOR CCGGCATATGAACATCGACATGGCTGCTCTGCATGCC Amplification of NusA from gDNA† 
NusA AMP REV ACGCGGATCCTTAGCGGTCGTGCGCCATACCGC Amplification of NusA from gDNA† 
NusG AMP FOR GCGCCATATGGTGACTACCTTCGACGGT Amplification of NusG from gDNA† 
NusG AMP REV GCGCCTCGAGCTAGATCTTGGAGACTTG Amplification of NusG from gDNA† 
• Restriction sites are in bold and mutagenesis sequences are underlined. †: H37Rv genomic DNA (gDNA) 




pET19bpps-CarD Expression of MTB CarD 
pET19bpps-NusA Expression of MTB NusA 
pET19bpps-NusG Expression of MTB NusG 
pMt-rrnA3 Template manipulation vector for assays 
pMt-rrnA3-synB Open-promoter half-life determination 
pEC19 Amplification of EC19 template 
pEC26-Tuf Amplification of Tuf terminator containing template 
pEC26-MetK Amplification of MetK terminator containing template 
 







Appendix Table III-A3: Percent of active RNAP from each preparation as determined 
from primer extension. Percent activity was calculated by 
dividing the sum of density for the 7-mer and 9-mer by the total 
density in the lane for each RNAP. Values are averages derived 
from three independent measurements. 
 











Appendix Figure III-A1: Sequence of source DNA template used in Chapter III. 
Sequence is of native H37Rv genomic DNA (+1468189 to 
+1468605) -66 to +351 of the transcription start site of the rrnA3 
promoter. The -10 and -35 elements are highlighted and the 
transcription start site is in green. Sites of mutagenesis are also 
highlighted. Endogenous MscI restriction site used for pEC26 






Appendix Figure III-A2: SDS-PAGE of all proteins used in Chapter III. RNAPs (left 




Appendix Figure III-A3: Gel images and plots for determined open-promoter 
complex half-life. A) Gel images used to determine open-
complex stability for each RNAP in the presence and absence 
of CarD. B) Plots showing the decay of the open-promoter 
complex over time for each of the RNAPs in this study. All 





Appendix Figure III-A4: Plots used to determine the elongation rate for MTB RNAPs. 
Density of runoff transcript was plotted against time. The time 
at which 50% of elongating RNAPs reach runoff length was 
divided by the length of the transcribed region to determine the 
average elongation rate. Phosphorimage of elongating MTB 
RNAPs. Time points for all RNAPs except the βS450L mutant 
(min): 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 5, 15. Time points 









Appendix Figure III-A5: Effect of NusA and NusG on elongation rate with WT MTB 
RNAP. Time points are as follows: 0.25, 0.5, 0.75, 1, 1.25, 1.5, 




High-throughput Screening to Identify Inhibitors of the M. tuberculosis 
Transcriptional Regulator CarD•RNAP Interaction 
 As mentioned in previous chapters RNA polymerase represents an attractive 
therapeutic target, when its function is compromised it is proven to be effective in bacterial 
killing. Several bacterial RNAP inhibitors have been identified over the last few decades 
(see Figure I-7); however, only two have made it to the clinic, Rifampin and Fidaxomicin. 
Unfortunately, resistance to many of these inhibitors has been reported when MTB is 
challenged with the compounds. Traditionally, most of the work in identifying methods of 
targeting RNAP have focused on the enzyme activity; however, RNAP functionality in vivo 
is significantly more complex, requiring several trans-acting factors which are essential 
for proper gene regulation and viability.1-2  
 In the case of MTB, several transcription factors have been shown to be required 
for proper transcription and organism viability, one of these factors is the global 
transcriptional regulator CarD.1, 3 Mycobacteria form relatively unstable open-promoter 
complexes (RPo) where promoter DNA is unwound. CarD is required for stabilization of 
these complexes.4-5 CarD exists in two subdomains, its N-terminal domain (1-53) interacts 
with MTB RNAP at the β1β2-lobes of the β-subunit, also known as the “protrusion”. Its C-
terminal domain (64-162), which is separated from the N-terminal domain by a 10-amino 
acid linker, interacts with promoter DNA at the upstream fork junction.6-7 CarD is required 
for MTB viability and mediation of stress responses such as exposure to antibiotics and 
123 
 
oxidative stress.1, 3 CarD’s function as a global transcriptional regulator that is required 
for MTB survival makes it a potential novel therapeutic target. 
 In this chapter, the development, optimization, and the validation of a fluorescence 
polarization assay to monitor the interaction between CarD and the RPo is presented. A 
pilot screen (237 compounds) was conducted to determine the viability of this assay for 
high throughput screening (HTS) prior to performing a 23,320 small molecule HTS. Hits 
from this screen were characterized in biochemical, biophysical, and bacterial assays for 
validation and to probe their mechanism(s) of action. 
Materials and Methods 
Protein Manipulation, Purification, and Labeling 
 Wild-type CarD was prepared as described in Chapter III and MTB RNAP was 
prepared as described in Chapter II. Mutant CarD variants were produced by 2-step 
mutagenesis using primers described in Appendix Table IV-A1. For fluorophore-labeled 
CarD, BL21(DE3) E. coli transformed with each pET19bbps-CarD plasmid was grown to 
an OD600 of 0.6 in 2xTY and induced with 1mM IPTG for 4 hours at 28°C. Cells were 
harvested and pellets from 1L of culture were resuspended in 20 mL of Lysis Buffer (20 
mM Tris HCl (pH 8.0), 500mM NaCl, 0.1mM EDTA, 5% glycerol (v/v), 5mM β-
mercaptoethanol (BME)). Before lysis, the suspension was supplemented with 2 mM 
PMSF, 1X Roche Protease cocktail, 1 mg/mL lysozyme, and 200 U DNaseI. Cells were 
disrupted by sonication and subsequently pelleted via centrifugation at 30,000 x g for 45 
minutes at 4 °C. Clarified lysate was sterile filtered and applied to a 1 mL HisTrap HP 
column. CarD was eluted by step gradient to 500 mM imidazole after extensive washing.  
124 
 
 To remove imidazole and ME, CarD was precipitated with 0.3 g/mL of ammonium 
sulfate followed by rinsing the protein pellet with Labeling Buffer (100 mM Tris HCl (pH 
7.5 at 25°C), 100 mM NaCl, and 1mM EDTA) with the same concentration of ammonium 
sulfate after which the protein was pelleted via centrifugation for 30 min at 3,000 x g. 
Precipitated CarD was resuspended in Labeling buffer to 2 mg/mL or until the solution 
was clear. To ensure all cysteines were reduced a 10-fold molar excess of freshly made 
TCEP solution was added and allowed to incubate at 25°C for 1 hour prior to labeling. In 
complete darkness 10-fold molar excess BODIPY™ FL iodoacetamide (N-(4,4-difluoro-
5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-yl)methyl)iodoacetamide, Thermo Fisher 
Scientific) suspended in dry DMF was added dropwise to the CarD solution with stirring. 
The reaction was allowed to proceed for 2.5 hours before excess ME was added to 
quench the reaction. The reaction was diluted in lysis buffer and reapplied to 1 mL of 
NTA-Ni2+ agarose, where it was allowed to incubate for 1 hour. The applied solution was 
allowed to flow through and the resin was washed with 5 mL of lysis buffer, then eluted 
with 5 mL of lysis buffer with 500 mM imidazole. Precission protease was added to the 
solution which was then dialyzed overnight in SEC Buffer (20 mM Tris HCl (pH8.0), 
300mM NaCl, 0.1mM EDTA, 5% glycerol, and 2 mM DTT). 
 To remove the Precission protease, the dialyzed protein was allowed to flow 
through 1 mL of glutathione agarose before being concentrated to ~0.5mL followed by 
application to a Superdex 200 10/300 GL column equilibrated with SEC buffer. Fractions 
containing labeled CarD were concentrated to >1 mg/mL, flash frozen with N2(l) and stored 
at -80°C. The extents of labeling of the dye-conjugated CarD proteins were confirmed 
both spectroscopically using Equation (1), where A504 is the absorbance of sample at 
125 
 
504 nm and ɛ504 is the extinction coefficient for BODIPY ™ FL (68,000 M-1•cm-1) as well 
as by LCMS (see Appendix Table IV-A2 and Figure IV-1-9). Labeling efficiencies 
ranged from 40-100% and are described in Appendix Table IV-A2. 










RNA polymerase binding protein (RbpA) from Mycobacterium smegmatis was 
purified in a similar fashion to that described by Dey et al.8 In brief, pETMsRbpA 
transformed BL21(DE3) cells were grown to an OD600 of 0.6 after which cells were 
induced at 30°C for 4 hours with 1 mM IPTG. Cells from 1 L of culture were resuspended 
in 20 mL of lysis buffer and disrupted by sonication. Clarified lysate was filtered and 
applied to a 1 mL HisTrap HP column and eluted with a 10-column volume linear gradient 
of 20 to 500 mM imidazole in lysis buffer. Fractions with RbpA were concentrated and 
applied to a Superdex 200 10/300 GL column equilibrated with SEC buffer. Purified RbpA 
was concentrated to 4 mg/mL, frozen in N2(l), and stored at -80°C.  
CarD Fluorescence Polarization Assay 
 The fluorescence polarization (FP) assay was conducted as described below in a 
final volume of 20 µL. Optimized CarD FP assay buffer contains 20 mM Tris HCl (pH 7.9 
at 37°C), 150mM potassium glutamate (KGlu), 10 mM MgCl2, 0.1mM EDTA, 0.01% Triton 
X-100, 5mM DTT unless noted otherwise. For binding isotherms used to determine 
dissociation constants (KD), BODIPY-labeled CarD tested at 1 nM, 3 nM and 5 nM, rrnAP3 
and artificial bubble DNA fragments (the latter of which has a 12 base noncomplementary 
region from -11 to +1 of the TSS, Appendix Table IV-A1) were kept constant at 1 µM 
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when used. WT MTB RNAP was typically titrated from 1 µM down to 244 pM. Assay 
components were allowed to incubate in a humidified incubator at 37°C for 2 hours in a 
black Corning® low volume round-bottom non-binding surface 384-well plate before 
reading in a BioTek Synergy H1 Hybrid Multi-mode plate reader preheated to 37°C. Wells 
were read at a sensitivity of 100 with 15 flashes per well at an excitation of 485/20 nm 
and emission of 528/20 nm. Fluorescence polarization (P) was determined by subtracting 
a blank well containing all assay components except BODIPY-labeled CarD from both the 
parallel (FII) and perpendicular (F┴) intensities and Equation (2) was used to determined 
polarization. FP values for binding isotherms were fit to a sigmoidal dose-response with 
variable slope described in Equation (3), where Y = millipolarization (mP) and X = 
concentration of receptor. KD was determined by averaging of the KD determined at the 3 
concentrations of CarD-BODIPY, each conducted in triplicate. 









 To determine IC50 and Ki for WT and mutant CarDs, competition experiments were 
performed as follows. In a 20 µL final volume of 1x CarD FP Buffer 15 nM MTB RNAP 
(1.25x the KD) and 300 nM rrnAP3 DNA fragment were kept constant. For determination 
of Ki, CarD-D68C-BODIPY was tested at 1 nM, 3 nM, and 5nM final concentration. WT, 
R47E, and K90A mutant CarD each were each tested from 20.5 µM down to 625 pM. For 
determination of small molecule IC50 competition experiments, CarD-BODIPY was held 
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constant at 3 nM and DMSO was added to a final concentration of 5% (v/v). IC50 was 
determined using Equation (4) and Ki was determined from Equation (5) from 3 
independent experiments, each conducted in triplicate, at 3 CarD-BODIPY 
concentrations which were averaged for the final Ki. Where [I]50 is the concentration of 
competitor at 50% inhibition (i.e., IC50), [L]50 is the concentration of free labeled ligand at 
50% inhibition, [P]0 is the concentration of free protein at 0% inhibition, and KD is the 
dissociation constant for the CarD•RPo complex. 













 A pilot screen of 237-pure small molecules from AnalytiCon was conducted as 
follows. Reaction conditions are described above with the following differences, 1 µL of 
each compound was deposited into individual wells followed by MTB RNAP, which was 
allowed to pre-incubate with compound for 20 minutes at 37°C prior to the addition of 
rrnAP3 DNA and CarD-D68C-BODIPY, final concentration of each compound was 25 µM. 
All components were allowed to incubate at 37°C for an additional 2 hours before reading 
the plate as mentioned above. For the negative control, reactions contained DMSO and 
for the positive control, RNAP was excluded. The z-score (Z) was calculated using 
Equation (6), where σP and σN are the standard deviation of the positive and negative 
controls and µP and µN are the mean of the positive and negative controls respectively. 
Hits were characterized as those which caused a decrease in mP greater than 3 standard 
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deviations from the negative controls. Compounds which met these criteria were tested 
in triplicate. For compounds that reconfirmed, concentration-response curves were 
generated. 




Primary High Throughput Screen 
 A high throughput screen (HTS) of the Maybridge 24K (MB24K) library (23,320 
compounds) was conducted using the CarD FP assay. Assay conditions were similar to 
those for the pilot screen described above with the following differences. The CarD FP 
assay was conducted at 25°C, therefore the buffering conditions were altered so that the 
pH was consistent with conditions tested above at 37°C. A shift in KD for the interaction 
of CarD with the RNAP•DNA complex (8 nM at 25°C, see Appendix Figure IV-A10) 
resulted in the use of 10 nM of RNAP (1.25x KD) for the screen. CarD-D68C-BODIPY was 
kept constant at 5 nM and rrnAP3 at a constant 300 nM. All other buffer conditions were 
as described above.  
First, 10 µL of 2x MTB RNAP was added to the 384-well plate using a multidrop 
dispenser (Thermo Fisher Scientific) followed by 200 nL of compound or DMSO using a 
Biomek FX HDR pintool instrument (Beckman Coulter) so that final concentration in the 
assay was 20 µM. Compounds were allowed to incubate with MTB RNAP for 20 minutes 
before addition of 10 µL of 2x CarD-D68C-BODIPY and DNA, again with the multidrop 
dispenser to a final volume of 20.2 µL. For negative controls DMSO without compound 
was used and for positive controls MTB RNAP was excluded. Reactions were allowed to 
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come to equilibrium at 25°C for 2 hours, after which plates were read on a PHERAstar 
FSX plate reader using 485/20 excitation and 520/20 emission fluorescence polarization 
filters. 
Confirmation, Counter Screen, and Concentration Response Screen 
 Compounds which met hit criteria (see Figure IV-8) were tested as in the primary 
screen in triplicate. A counter screen was conducted to detect compound interference 
with CarD-D68C-BODIPY fluorescence in the absence of MTB. This assay was 
conducted similar to that of the primary and confirmation screen with the following 
difference. Substituting for the 10 µL 2x MTB RNAP, 10 µL of 1x reaction buffer was 
added to the well with the multidrop dispenser. All compounds which were processed for 
confirmation were tested in this assay, again in triplicate. Plates were handled in the same 
fashion as for the primary screen. Compounds which confirmed and met criteria set for 
the counter screen were tested in duplicate for concentration-dependent inhibition and 
were derived from separated stock plates. For concentration-response studies, 200 nL of 
compound (final concentrations were varied from 150 – 4.2 µM; 1.67x dilutions) or DMSO 
were dry spotted into 384-well plates prior to addition of any of the assay components 
using a Mosquito X1 dispenser and plates were centrifuged. Assay components were 
then added as described above. 
Reconfirmation 
Reconfirmations with purchased, fresh solid/powder compounds were performed 
essentially as described above. Fresh compounds were resuspended in DMSO and 1µL 
deposited into a 384-well plate (Final concentration:1000 µM to 0.46 µM). To the 384-well 
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black low volume U-bottom plate 1 µL of compound was added. Using the multidrop, 9 
µL of a 22.2 nM RNAP solution in 1x CarD FP buffer was added and allowed to incubate 
with the compounds for 20 minutes at 25°C before addition of 10 µL of a 2x CarD D68C 
BODIPY and rrnAP3 DNA solution. The reaction was allowed to come equilibrium over 2 
hours at 25°C and then read on the PHERAstar or Biotek H1 Synergy plate reader. The 
data were processed as previously described. 
Surface Plasmon Resonance 
Surface plasmon resonance experiments were performed on a SensiQ Pioneer 
instrument using a HisCap biosensor (Pall FortéBio) with 3 channels in series. N-terminal 
decahistidine tagged CarD was prepared as described in Chapter III with the following 
modification: SEC buffer used during the final purification step contained 10 mM HEPES 
(pH 8.0), 300 mM NaCl, and 5% glycerol. CarD was stored as previously described. 
Channel 1 was charged 20 µL of 50 µM NiCl2 at a flow rate of 10 µL/ minute followed by 
His-tagged CarD which was immobilized by injecting a 4 µg/ mL solution of CarD 
suspended in CarD SPR buffer (10 mM HEPES (pH 8.0 at 25°C), 150 KCl, 0.01% Triton 
X-100 and 5% DMSO) for 8.5 minutes at an injection speed 10 µL/ min. All compounds 
tested were lyophilized prior to being resuspended in SPR buffer. Compounds were 
tested at 100 µM, 75 µM, 50 µM, 25 µM, and 12.5 µM (unless otherwise noted) in a 
random order with periodic blanks every 5 sample injections at a sampling rate of 10 Hz. 
Each injection consisted of a 100 µL of sample at a flow rate of 50 µL/ minute. Response 
curves were normalized to blank injections and association rate (ka), dissociation rate (kd), 
and binding constant (KD) were determined by fitting to a 1:1 interaction model using Qdat 
software. As a counter screen, all compounds which showed concentration dependent 
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response with CarD were tested for binding to eIF4E, a human translation factor which 
was a gift from the Garner lab. Due to eIF4E’s poor thermal stability, reactions with eIF4e 
were run at 15°C. 
Results 
CarD Fluorescence Polarization Assay 
To develop the fluorescence polarization (FP) assay, site-specific mutagenesis of 
several selected residues on CarD to cysteine was performed followed by chemical 
modification by BODIPY iodoacetamide. Labeling efficiency of the CarD mutants varied 
from ~40%-100% (see Appendix Table IV-A2). Labeling sites were explored on both the 
N-terminal RNAP-interacting domain (RID) and the C-terminal DNA-interacting domain 
(DID). The dynamic range and KD of each of the BODIPY-labeled CarD mutant were 
characterized by titration with WT MTB RNAP (see Figure IV-1). 
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Figure IV-1: Characterization of labeling sites on CarD. A) Sites on CarD which were 
selected for site-specific mutagenesis and subsequent labeling with 
BODIPY FL (colors correspond with binding isotherms in B). B) Binding 
isotherms for CarD mutants labeled with BODIPY FL (note: several 
differences in this assay are as follows: 50 mM KGlu. 0.001% Triton X-100, 
and 12.5 nM BODIPY-labeled CarD were used in this experiment). C) 
Summary of isotherm parameters for each CarD variant as well as domain 
interaction on the RPo where BODIPY probe is located.  
 
Several mutant labeled CarD’s produced discernable binding isotherms, though 
the range and affinity varied for each of the mutants (see Figure IV-1). Of the six variants 
explored, labeling at position D68 produced a binding isotherm with the greatest dynamic 
range (ΔmP = 169.3) and had the strongest affinity for the RPo (KD = 29 nM, under the 
conditions tested). Several other labeled CarD mutants also produced binding isotherms 
(T8C and S162C) though the dynamic range was significantly smaller (ΔmP ~40) and 
they had lower affinity (KD ~ 65 nM), which may suggest the probe could be interfering 
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with binding. There were small responses, ΔmP = 23.9 and ΔmP = 15.1, for CarD T152C 
and CarD T26C respectively. For CarD T26C an inverse binding isotherm was observed, 
possibly due to the propeller effect on the BODIPY probe upon binding to the RPo 
complex. The labeled D68C CarD mutant was used for all further CarD FP studies.  
Optimal binding conditions for the CarD•RPo interaction were explored as was the 
stability of the FP in the presence of DMSO and over time (see Figure IV-2). Binding 
isotherms for CarD•RPo was monitored in titration experiments with both NaCl and 
potassium glutamate (KGlu) (see Figure IV-2A-B). Increasing concentrations of NaCl 
resulted in complex destabilization above 100 mM NaCl. The ternary complex was 
significantly more resistant in the presence of KGlu with isotherm contours still 
discernable up to 500 mM KGlu though a decrease in dynamic range is evident. Final salt 
conditions were a final concentration of 150 mM KGlu. The assay signal was also found 
to be stable over 24-hours (see Figure IV-2C). Addition of DMSO to ternary complex at 
RNAP concentrations (1.25x the KD or 15 nM, see below) shows that the assay can 
tolerate DMSO up to 5% without significant deviation from the negative control (see 
Figure IV-2D).  
134 
 
Figure IV-2: Optimization of CarD FP Assay. A) Stability of the CarD FP assay with 
NaCl titration. B) Stability of CarD FP assay with KGlu titration. C) Temporal 
stability of the CarD FP Assay at 37°C (for stability at 25°C see Appendix 
Figure IV-A10). D) Tolerance of CarD assay in the presence of increasing 
DMSO. 
 
Binding isotherms were produced using labeled CarD with promoter DNA and 
RNAP only, as well as, with both native rrnAP3 RPo and a DNA fragment with an artificial 
bubble from -11 to +1 to determine dissociation constants, KD (see Figure IV-3). 
Dissociation constants for each of the components mentioned above were determined in 
three independent experiments done in triplicate with varying concentrations of labeled 
CarD (1nM, 3nM, and 5nM), the average of all three experiments were considered for 










DNA fragments up to 30 µM. RNAP only (no DNA) concentrations were tested up to 1 
µM; however, a complete binding isotherm could not be generated from the 
concentrations tested. An estimate of ~2 µM for the RNAP•CarD KD was made by 
extrapolating the RNAP only binding curve to the maximum mP observed in the presence 
of DNA. The affinity for the RPo using the “native” rrnAP3 DNA fragment was determined 
to be 12 ± 2 nM and for the artificial bubble DNA 18 ± 2 nM (see Figure IV-3). 
Figure IV-3: CarD affinities for DNA, RNAP, and the open-promoter complex (RPo). 
A) Schematic of CarD binding partners with dissociation constants derived 










Competition and Preliminary Inhibition Experiments 
Competition experiments were performed using 15 nM RNAP (1.25x KD) and 
“native” rrnAP3 DNA template at 300 nM which was determined to be the minimal amount 
of DNA needed to maintain RPo complex stability (see Appendix Figure IV-A11). 
Experiments were performed in triplicate at three concentrations of labeled CarD (1 nM, 
3 nM, and 5 nM). The inhibition constant (Ki) for WT unlabeled CarD was determined to 
be 8 ± 1 nM, which is similar to the KD of CarD-D68C-BODIPY for the “native” RPo 
complex, indicating that the BODIPY probe does not interfere with CarD binding to RPo 
(see Figure IV-4). Inhibition constants were also determined for two CarD mutants, R47E 
which disrupts the CarD N-terminal interaction with RNAP and K90A which has been 
shown to disrupt CarD interactions with promoter DNA.9-10 CarD R47E (Ki = 129 ±14 nM) 
and CarD K90A (Ki = 85 ± 6 nM) show decreased affinity for the RPo complex, 




Figure IV-4: Competition experiments with unlabeled CarD variants. A) Competition 
curve showing displacement of BODIPY-labeled CarD by WT and mutant 
CarD proteins (RNAP present at 1.25x KD as determined in Figure IV-3). 
B) Summary of binding and inhibition constants as determined using 
Equation 5. 
 
To test the capability of the CarD FP assay to monitor the presence of DNA within 
RNAP, the IC50 of Fidaxomicin was determined (see Figure IV-5). Fidaxomicin (FDX) 
binds to the “switch” domain of RNAP locking it in an “open” clamp conformation 
preventing DNA from being securely bound within RNAP.11-13 This experiment was 
conducted with both “native” and artificial bubble DNAs as well as in the presence and 
absence of M. smegmatis RNA polymerase binding protein, RbpA, which is required for 
Fidaxomicin potency against mycobacterial RNAPs.  In the absence of RbpA, the 
observed IC50 is 6 µM which is in agreement with inhibition observed with FDX in an in 














is significantly higher (IC50 < 80 µM), the artificial bubble template shifts the equilibrium of 
RPo toward the “closed” clamp configuration which has a dramatically lower affinity for 
FDX. In the presence of RbpA, the “native” DNA template exhibits an increase in FDX 
potency to an IC50 of 0.24 µM, which is consistent with other results recently reported.11 
In the presence of RbpA and the artificial bubble template, the IC50 for FDX is 0.3 µM, 
which indicates that RbpA is able to overcome the reduction in affinity for FDX observed 
when using the artificial bubble template (see Figure IV-5). 
 
Figure IV-5: Fidaxomicin inhibition of CarD association with RPo. A) Structure of 
Fidaxomicin. B) CarD binding to RPo in the presence of varying 
concentration of FDX with “native” rrnAP3 and artificial bubble DNA. C) 
Summary of inhibition data with and without RNA polymerase binding 
protein with both the CarD FP compared to literature values. 











A pilot screen of 237-pure small molecule library from AnalytiCon was conducted 
to evaluate the efficacy of the CarD FP assay for HTS (see Figure IV-6). For negative 
controls (n = 90) DMSO only was included (5% v/v) and for the positive control (n = 52) 
MTB RNAP was omitted. A Z-score = 0.77 was calculated using Equation (6) and the 
preliminary hit rate was determined to be 5% (12/237). All compounds were tested in 
triplicate and a single compound was found to confirm. It was determined that several 
false positives were identified from edge effects likely due to thermal variation along the 
edge of the plate (assay run at 37°C). During concentration response for the compound 
in question, it was determined that this compound likely has a fluorescent contaminant 
present in the sample and was also deemed a false positive. Though no hits were 
identified, this pilot demonstrated this assay is well suited for a larger HTS campaign.  




Primary High Throughput Screen 
A 23,320-compound small molecule library (Maybridge 24K) was screened using 
the CarD FP assay (see Figure IV-7A). Due to thermal edge effects observed in the pilot 
screen this assay was run at 25°C instead of 37°C. At this temperature the assay has a 
reduced dynamic range (ΔmP = 138) and a modest increase in the affinity of CarD for the 
RPo (KD = 7.5 nM) (see Appendix Figure IV-A10). For the primary screen 10 nM WT 
MTB RNAP (1.33x KD) was used which resulted in a dynamic range of ΔmP = 76.9. The 
Z-score for the primary screen was determined to be 0.73.  
 
 
Figure IV-7: Maybridge 24K HTS with the CarD FP assay. A) Percent activity and B) 
parallel intensity of primary screen results (Positive controls (Red), 











Several criteria were used to identify hits for this screen, 995 compounds or 4.26% 
were at least 3 standard deviations (3σ) from the negative controls; however, there were 
a significant fraction of these which were found to be from compound interference with 
the assay and others which were red and black flagged by the NIH. Compounds which 
were >110% percent active (relative to the positive control on a plate by plate basis) were 
eliminated from the hit pool (96 compounds removed). These compounds are either false 
positives from fluorescence interference or are causing denaturation of the proteins in the 
assay. Additionally, compounds were eliminated from the hit pool if they caused an 
increase in the parallel intensity > 3σ from the average of the positive and negative 
controls or 29600 RFU (357 compounds removed, see Figure IV-7B). Compounds which 
were designated as red or black flag compounds were eliminated from the final count (62 
compounds removed). Finally, a promiscuity filter was applied to eliminate compounds 
which hit in more than 9 other screens (58 compounds removed). After all filters were 
applied the final hit rate was 1.8% (422 / 23,320), which is substantially higher than the 
anticipated 1% hit rate. 
Confirmation, Counter Screen, and Concentration Response Screen 
All 422 compounds which were designated “hits” from the primary screen were re-
tested in triplicate from the same stock plate of compounds. The Z-score for the retest 
plates was 0.76 (see Appendix Figure IV-A12A). Compounds which were >3σ from the 
negative controls in triplicate were considered confirmed hits (202 compounds removed). 
Additionally, compounds which were greater than or equal to 3σ parallel intensity of the 
negative control and equal or less than 3σ of the positive control were advanced (30 and 
11 compounds removed respectively). All flagged PAINs (pan-assay interference 
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compounds) and compounds with a clogP > 5 were removed (39 compounds removed 
total). At this point 134 compounds remained (0.57% of the primary screen). A counter 
screen was conducted to eliminate compounds which interfered with BODIPY-labeled 
CarD parallel fluorescence intensity (24 compounds removed) and fluorescence 
polarization (10 compounds removed) by more than 3σ (see Appendix Figure IV-A12B).  
At this stage there were 109 compounds, or 0.47% of the primary screen remaining. Of 
the 109 compounds 100 were selected for concentration-response studies (CRC), 59 
compounds were designated as a positive result in the CRC study (see Figure IV-8). 
 
Figure IV-8: Schematic of criteria for selection of hits from the primary screen to 




≥ 3σ Negative Controls (22,325)
<110% active (96) 
< 3σ parallel intensity of Negative control (357)
No red or black flags (62)
422 Hits (1.8%)
Reconformation
≥ 3σ Negative Controls in triplicate (202)
3σ ≤ Parallel Intensity Negative control (30) 
≥ 3σ Parallel Intensity Positive Control (11)
No PAINS and clogP < 5 (39)
134 Hits (0.57%)
Counter Screen (CarD-Bodipy only)
3σ > Parallel Intensity < 3σ (24)
3σ > mP < 3σ (10)
109 "Hits" (0.47%)
Concentration Response Curves (100)
59 Active Concentration Response Curves




All 33 fresh powder samples were characterized by LCMS. Two of the 33 
compounds were found to be either completely degraded or their MW did not match the 
labeled compound. All other fresh powders did match the MWs of the labeled compounds; 
however, the purities ranged from <50% to >95%, with the vast majority being the latter. 
Fresh powders ordered were tested in the CarD FP assay. Of the 33 compounds tested, 
8 compounds were considered as hits (see Table IV-1, Appendix Table IV-A3), either 
because they have an IC50 below 200 µM, they are part of a cluster, or they showed direct 
binding via SPR (see below and Appendix Figure IV-A13). A single cluster (compounds 
with a similar structure) was identified (MAS-1 and MAS-2, see Table IV-9). Though very 
weak inhibitors, three of the compounds identified have IC50s less than 100 µM. Eleven 
of the fresh powders did not reconfirm and several other compounds had extremely weak 
inhibition (>>200 µM). One compound was found to be a non-specific binder by SPR. The 
physiochemical properties of these compounds can be found in Appendix Table IV-A3. 




MAS-1 I 37 680 
MAS-2 I 78 160 
MAS-16 II 106 37 
MAS-23 III 15 188 
MAS-25 IV 250 132 
MAS-26 V 90 47 
MAS-28 VI 60 200 
MAS-29 VII 106 85 
Table IV-1: Reconfirmed hits from fresh powders for the CarD MB24K HTS.  
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Surface Plasmon Resonance 
All compounds ordered were screened by surface plasmon resonance (SPR) 
against decahistidine-tagged CarD which was immobilized on a HisCap biosensor. Of the 
33 compounds tested (in duplicate at 75 µM), 11 compounds elicited a response. A full 
concentration dependent screen was then conducted with all 11 compounds. Of these 11 
compounds 4 confirmed, 2 are designated as weak binders (MAS-1 and MAS-2) because 
of the overall low response (< 5 response units (RU)) and 2 compounds are binding CarD 
in a concentration-dependent manner (MAS-16 and MAS-19). MAS-16 is the most 
promising of the set (KD = 6.4±0.02 µM), it has a slow on rate of 385.5±0.8 M-1s-1 and 
slow off rate of 2.48±0.004 x 10-3 s-1 (see Figure IV-9). Even though MAS-19 has a 
significantly weak IC50 it appears to have a KD of 8.91±0.02 µM with CarD. MAS-1, -2, -
16, and -19 were also screened against eukaryotic initiation factor 4E (eIF4E), which is 
involved in translation in humans to determine whether the observed response with CarD 
was non-specific (CarD and eIF4E share 8.4% sequence similarity). MAS-19 was found 
to bind to eIF4E (KD = 28±0.1 µM) in a similar fashion to CarD so it was eliminated as a 
potential hit (see Figure IV-9). Response curves for MAS-16 for eIF4E had to be fit with 
a two-state binding fit due to the biphasic nature of the responses. MAS-16 showed very 
low binding to eIF4E, with an affinity of 120±30 µM for the first site and 3±1 mM for the 
second site. Saturation was never reached for MAS-16 against eIF4E at any 
concentration of MAS-16 tested. Due to the limit of compound solubility, MAS-16 was only 
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Figure IV-9: Monitoring direct binding of small molecules to CarD and eIF4E by 
SPR.  A) Structures of MAS-16 and MAS-19. B) Response curves for both 
MAS-16 and MAS-19 for CarD and eIF4E. C) Summary of kinetic data 




















 Identification of new antibiotics which act my novel mechanisms of action is critical 
for addressing rising levels of antibiotic resistance. Targeting transcription in bacteria is a 
viable method for bacterial killing, as evidenced by the success of both Rifampin and 
Fidaxomicin. Traditionally, people have targeted RNA polymerase; however, productive 
transcription is a complex process which is highly regulated. We believe that this 
regulation represents an attractive target for novel antibiotic discovery. CarD is a global 
transcriptional regulator which has been shown to be required for MTB viability.3, 9, 14 
While the effect of CarD on other organism’s viability has not been explored, it’s presence 
in other clinically relevant organisms represents a unique opportunity to be a novel broad-
spectrum target.  
 A highly robust fluorescence polarization assay which probes the interaction 
between CarD and the RPo (open-promoter complex) was developed and utilized to 
identify novel antibiotic chemical matter. CarD lacks endogenous cysteine residues which 
allowed for site-specific incorporation of a BODIPY FL probe using site-directed 
mutagenesis and thiol reactive conjugated probe (see Figure IV-1). Percent labeling was 
monitored both spectroscopically and via LCMS. LCMS results indicate >90% labeling in 
all cases with the exception of CarD S162C mutant, where labeling was determined to be 
40% by UV/Vis methods and 50% by LCMS (see Appendix Table IV-A2). This is likely 
because cysteine at this position has a pKa which is significantly higher than the standard 
pKa ~8.0 of cysteine due to the proximity to the C-terminus.15-16 Differences in labeling 
efficiencies between the UV/vis methodology and LCMS are likely due to the local 
environment of the BODIPY probe causing a shift in the observed excitation or emission 
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maxima or could be effecting the extinction coefficient or quantum yeild;17-18 therefore, we 
believe the LCMS results more accurately reflect percent labeling of CarD mutants.  
 Not surprisingly NaCl cause destabilization of the RPo which was exacerbated with 
increasing concentrations of NaCl (see Figure IV-2A-B).4 The Cl- anion has been 
reported to cause destabilization of the RPo and our data reflects previous reports of 
CarD efficacy on stabilization of the RPo.4 The RPo was more resistant to challenge by 
KGlu, which is actually the more prevalent anion (glutamate) found in vivo making this 
assay more reflective of physiological conditions.19-20 In preparing for the use of this assay 
for HTS, we found that our signal is stable for over 12 hours at 37°C (longer times not 
tested), but under screening conditions at 25°C the signal stability extended up to 48 
hours (see Figure IV-2C, Appendix Figure IV-A10B). DMSO cause increase in 
polarization of CarD•RPo at concentrations above 10% (v/v), likely effecting the 
organization of water which would affect CarD tumbling in solution but did not have an 
effect at the maximum DMSO concentration used, 5% (v/v)(see Figure IV-2D).21-22  
CarD requires DNA to be present for high affinity interaction RNAP (12nM vs 2 µM 
without DNA at 37°C). This binding affinity is consistent with predicted binding affinity 
determined by rate constants determined using stop flow experiments. Their reported 
value is 6.7 nM at 25°C whereas we recorded the interaction to have a dissociation 
constant of 7.5 nM at 25°C (see Appendix Figure IV-A10).5 The interaction with the RPo 
is roughly 170x’s tighter than when DNA is not present. Endogenous concentrations of 
CarD in M. smegmatis are reported to be 1.6 µM as determined from quantitative 
immunoblotting, which would mean CarD may be partially bound to free RNAP in vivo. 
No significant hyperpolarization was observed in DNA titration experiments.5 The DNA 
148 
 
fragments used in this experiment at ~30,000 kDa which may not be large enough to elicit 
a response in the assay, typically a 10-fold difference in binding partner is required for a 
defined binding isotherm.  
Inhibition constants were performed to validate the FP assay and to determine 
whether the BODIPY probe may be interfering with CarD bind to the RPo. Competition of 
BODIPY-labeled CarD with WT unlabeled CarD resulted in a Ki = 8 nM, which is similar 
to the KD determined for CarD affinity for the RPo (see Figure IV-4). This suggests that 
the probe has little to no effect on CarD binding to the RPo. Using two unlabeled CarD 
variants, R47E which it at the interface between CarD and RNAP and K90A which has 
been shown in EMSA experiments to be involved in DNA binding, competitions 
experiments show that the interaction between CarD and either the interaction with RNAP 
or DNA are compromised with these mutations. This suggests that if either of these 
functions are disrupted you can reduce the affinity of CarD and thus destabilize the RPo.  
The differential binding affinity of CarD for free RNAP (~ 2 µM) compared to its 
affinity for the RPo (12 nM) broadens the repertoire of types of inhibitors that can be 
identified with this assay (see Figure IV-3). Since we are conducting the HTS at 10 nM 
where there is no polarization response from free RNAP we should be able to identify 
inhibitors of DNA association with RNAP. This was shown to be the case with Fidaxomicin 
(FDX). FDX block RNAP clamp closure onto DNA preventing unwinding of DNA.11, 13 
Recent reports demonstrated the involvement of another transcriptional regulator RNA 
polymerase binding protein (RbpA) in high affinity inhibition of RNAP (IC50 = 0.21 µM).11 
RbpA makes contacts with its N-terminal tail (NTT) with FDX. Using M. smegmatis RbpA 
(which shares >90% sequence similarity to the MTB homolog) we show that we can 
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monitor the effect of FDX in preventing DNA binding in our CarD FP assay (IC50 = 0.24 
µM) (see Figure IV-5). Therefore, we believe this vastly expands the utility of this assay 
in drug discovery related to inhibition of transcription in MTB. 
With the validated CarD FP assay a pilot screen on 237-purified small molecule 
natural products was conducted (see Figure IV-6). The Z-score for this assay was 0.77 
which indicates this assay is highly robust and amenable for larger HTS campaigns. 
Though no inhibitors were discovered using this library the assay provided empirical 
support for running the larger screen. Additionally, thermal edge effects observed with the 
pilot screen prompted running the larger campaign at 25°C. 
A 23,320-compound library (MB24K) was screening using the CarD FP assay. The 
z-score was 0.73 demonstrating the CarD FP assay has an excellent assay to use in a 
HTS format (see Figure IV-7A). The preliminary hit rate, based solely samples which 
were >3σ from the negative control, was 4.26%. This is significantly higher than the 
desired 1% hit rate for screening. BODIPY FL is a green-shift fluorophore, which can have 
significant overlapping excitation and emission spectra with compounds in libraries.23-24 
This is evident when you look at the parallel fluorescence intensity of the compounds in 
the primary screen (see Figure IV-7B). There are several reasons which may cause false 
positives such as autofluorescence and quenching by small molecules. To mitigate this, 
we eliminated compounds with parallel fluorescence intensities >3σ of the negative 
controls. Additionally, compounds which appeared to have >110% activity in the assay 
were eliminated, several of these were likely due to compound interference, but may also 
be from compounds causing denaturation of protein and/or may be directly interfering 
with the BODIPY probe. None of these compounds would be useful for drug discovery. 
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Compounds which are red or black flags by the NIH were also removed, using these 
criteria we were able to reduce our hit rate to 1.8%, which was still high.  
In reconfirmation 220 out of 422 compounds reconfirmed, reducing the hit rate to 
0.94%, which is ideal for a screen of this magnitude. Compounds whose parallel 
fluorescence intensity which deviated from both the positive and negative control were 
removed (41 total). All PAINs and compounds which had a clogP > 5 were also removed 
since these compounds would likely not be amenable lead candidates (39 compounds 
total), leaving us with 140 compounds or 0.57% of the primary screen. A counter screen 
was also run to eliminate compounds which altered parallel fluorescence intensity or mP 
of BODIPY-labeled CarD on its own. These compounds are likely directly effecting the 
BODIPY probe, removal of these compounds left us with 109 compounds or 0.47% of the 
primary screen (see Figure IV-8; Appendix Figure IV-A12B,C).  
Concentration response curves (CRC) were generated for 100 of 109 initial hit 
compounds. Several compounds which appeared to be DNA intercalators, had reactive 
or unstable moieties (such as redox cyclers), or were chemically unattractive were 
removed prior to CRC analysis. Out of 100 compounds 59 demonstrated some extent of 
concentration response. We did not identify any compounds with an AC50 < 10 µM, which, 
while unfortunate, was not unexpected since we screened against a limited library and 
perhaps more importantly because we are trying to identify a protein-protein or protein-
nucleic acid inhibitor. These types of inhibitors are notoriously difficult to identify because 
protein surfaces tend to lack contour and protein-nucleic acid interaction are usually, but 
not always non-specific.  
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Of the 33 fresh powder samples, only 8 are classified as hits at this point. Several 
compounds were eliminated either because of low potency, because they had steep hill 
slope (likely indicating inhibition due to aggregation), or they were non-specifically binding 
via SPR.25 We set our upper limit at 200 µM for several reasons: 1) we ran a limited 
screen, 2) protein-protein interactions are notoriously difficult to target, and 3) it is early 
on in the discovery process and we don’t want to potentially eliminate false negatives.26 
A single cluster consisting of MAS-1 and MAS-2 was identified (see Appendix Table IV-
A3). 
All 33 compounds were initially screened in duplicate at 75 µM against CarD via 
SPR. Of the 33, 11 elicited some response, though most were very weak binders. When 
we cross referenced these with the positives in our CarD FP assay, we had 4 compounds 
(MAS-1, -2, -16, and 1-9). MAS-1 and MAS-2 are very weak binders with responses below 
5 RU; additionally, a concentration dependent response could not be readily observed, 
likely due to non-specific interactions. MAS-16 and MAS-19 gave maximum responses 
above 10 RU in a concentration dependent manner. As a counter screen, eIF4E was 
immobilized on the chip and both MAS-16 and MAS-19 were screened. A full 
concentration response from MAS-19 was also observed against eIF4E so this compound 
was eliminated from out hit list (see Figure IV-9). MAS-16 appears to have a significantly 
lower affinity for eIF4E (KD = 120 µM) compared to CarD (KD = 6.43 µM), which indicates 
this compound has selectivity for CarD. While these results are promising we are 
cautiously optimistic, as these are preliminary results. MAS-16 and the other compounds 
will need to be validated with several alternate secondary assays as well as show 
reproducibility with purified and validated compounds.  
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Future directions for this project include identifying potential binding sited for MAS-
16 and MAS-19, in addition to determining whether the other identified hits are acting by 
preventing DNA association with RNAP. For the former project I propose using a 
computational approach by modeling in MAS-16 and MAS-19 to previously resolved 
structures of CarD using MOE (PDB: 4KBM). Models will be validated by using both 
alanine scanning and SPR to determine whether these residues are interacting with the 
compounds of interest. If these sites are validated, commercially available analogs should 
be purchased to improve potency. As for determining whether the other preliminary hits 
are disrupting the interaction between RNAP and DNA, the malachite green assay 
(described in Chapter II) or an electrophoretic mobility shift assay could be employed. 
While these are a few directions which could be explored, there are several directions 
which could be explored, including utilization of crystallography and NMR methodologies.   
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Appendix to Chapter IV 
Name Sequence Purpose 
CarD T8C FOR ATTTTCAAGGTCGGAGACTGCGTTGTCTATCCACACCAC CarD T8C Mutagenesis 
CarD T8C REV GTGGTGTGGATAGACAACGCAGTCTCCGACCTTGAAAAT CarD T8C Mutagenesis 
CarD T24C FOR GTCGAGGCGATCGAATGCCGGACCATCAAAGGGG CarD T24C Mutagenesis 
CarD T24C REV CCCCTTTGATGGTCCGGCATTCGATCGCCTCGAC CarD T24C Mutagenesis 
CarD T26C FOR CGATCGAAACCCGGTGCATCAAAGGGGAAC CarD T26C Mutagenesis 
CarD T26C REV GTTCCCCTTTGATGCACCGGGTTTCGATCG CarD T26C Mutagenesis 
CarD D68C FOR CGGGCAGGAAGGCCTGTGCAAGGTTTTCCAGG CarD D68C Mutagenesis 
CarD D68C REV CCTGGAAAACCTTGCACAGGCCTTCCTGCCCG CarD D68C Mutagenesis 
CarD T152C FOR GACGCCAAAGCCGAGTGCATCCTTGACGAGG CarD T152C Mutagenesis 
CarD T152C REV CCTCGTCAAGGATGCACTCGGCTTTGGCGTC CarD T152C Mutagenesis 
CarD S162C FOR GCCGCCGCGTGTTGAGGATCCGGCTGCTAACAAAGC CarD S162C Mutagenesis 
CarD S162C REV GCTTTGTTAGCAGCCGGATCCTCAACACGCGGCGGC CarD S162C Mutagenesis 
rrnAP3 FP TOP GATGACCGAACCTGGTCTTGACTCCATTGCCGGATTTGTATTAGACTGGCAGGGTT
GCCCC 















FP Assay DNA 
Appendix Table IV-A1: Primers used in Chapter IV. Mutagenesis sites are underlined 
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 m/z  
(Calculated) 
Percent Labeling 
CarD Mutant Unlabeled Labeled LCMS UV/Vis 
WT 18198.68 NA NA NA 
R47E 18171.60 NA NA NA 
K90A 18141.58 NA NA NA 
T8C-BODIPY 18200.71 18489.81 91% 96% 
T24C-BODIPY 18200.71 18489.81 97% 90% 
T26C-BODIPY 18200.71 18489.81 98% 67% 
D68C-BODIPY 18186.73 18475.83 100% 88% 
T152C-BODIPY 18200.71 18489.81 98% 87% 
S162C-BODIPY 18214.75 18503.85 52% 37% 
Appendix Table IV-A2: Characterization of mutant and BODIPY-labeled CarD 
variants. Mass of CarD variants derived from theoretical 
values, refer to Appendix Figures IV-1-8 for empirical values 









Appendix Figure IV-A1: LCMS Characterization of WT CarD. A) LC trace, B) 
fragmentation by MS, C) deconvoluted protein m/z, and D) 


























Appendix Figure IV-A2: LCMS Characterization of CarD R47E. A) LC trace, B) 
fragmentation by MS, C) deconvoluted protein m/z, and D) 


























Appendix Figure IV-A3: LCMS Characterization of CarD K90A. A) LC trace, B) 
fragmentation by MS, C) deconvoluted protein m/z, and D) 
magnification of peaks proximal to the protein m/z. 
  
























Appendix Figure IV-A4: LCMS Characterization of CarD T8C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 




























Appendix Figure IV-A5: LCMS Characterization of CarD T24C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 




























Appendix Figure IV-A6: LCMS Characterization of CarD T26C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 




























Appendix Figure IV-A7: LCMS Characterization of CarD D68C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 


























Appendix Figure IV-A8: LCMS Characterization of CarD T152C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 




























Appendix Figure IV-A9: LCMS Characterization of CarD S162C BODIPY. A) LC trace, 
B) fragmentation by MS, C) deconvoluted protein m/z, and D) 






















Appendix Figure IV-A10: CarD FP Assay at 25°C. A) Effect of temperature on CarD 
FP Assay B) CarD FP assay temporal stability over 48-hours. 
 
Appendix Figure IV-A11: Titration of rrnAP3 DNA in CarD FP assay. RNAP is present 
at 15 nM and CarD BODIPY at 3 nM. The dashed line is at 250 
nM and represents the threshold for the minimum amount of 











Appendix Figure IV-A12: Retest plate data for confirmation from MB24K primary. 
A) All compounds which were tested for confirmation in 
triplicate. B) Effect of compounds tested against CarD BODIPY 
alone on parallel fluorescence intensity in the counter screen. 
C) Effect of compounds tested against CarD BODIPY alone on 




















Appendix Table IV-A3: Physiochemical properties of reconfirmed hits from 
MB24K HTS.  
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Appendix Figure IV-A13: Curves used to generate IC50 values for hits from the 
MB24K HTS. Points deleted from MAS-16 due to compound 





Concluding Summary and Future Directions 
My dissertation work revolved around understanding the therapeutic potential of 
transcription in Mycobacterium tuberculosis. My first scientific goal was to acquire highly 
pure and catalytically active MTB RNA polymerase (RNAP), which would then be used in 
a series of biochemical assays. Using this purified enzyme, my next goal was to 
characterize the intrinsic properties of MTB RNAP to help explain the clinical prevalence 
of certain RMPR mutations. My final goal was to develop a fluorescence polarization assay 
to monitor binding of transcriptional regulator CarD to the RPo complex and to use this 
assay for high throughput therapeutic discovery. 
Initial attempts to use a polycistronic expression vector (pMTBRP) containing all 
the core subunits of RNAP were unsuccessful due to disproportionate overexpression of 
the subunits.1 A new methodology which used multiple vectors, some of which contained 
two of the RNAP subunits, was shown to be effective for overexpression of all subunits; 
therefore, efforts to optimize the pMTBRP expression system were discontinued (see 
Figure II-1).2 Several iterations of the multiple vector system were attempted (see Figure 
II-2-4) and a configuration involving three vectors which allowed for enrichment of 
stoichiometric MTB RNAP holoenzyme was identified (see Figure II-4). Initial 
characterization of the purified enzyme activity with primer extension analysis found that 
these purified complexes has very low specific activities (see Figure II-5C). A zinc-binding 
172 
 
domain (ZBD) in the β’-subunit of RNAP is involved in the proper folding of the subunit 
and assembly of catalytically-competent RNAP complex.3 This prompted the 
supplementation of growth media with ZnSO4. Complexes purified under these conditions 
were significantly more active than those purified without Zn+2 (see Figure II-5C). Purified 
complexes were also devoid of chromosomally-encoded E. coli RNAP subunit 
contamination (see Appendix Figure II-5). Therefore, a method by which highly pure and 
catalytically active MTB RNAP was successfully developed. 
Using this methodology, WT and RMPR mutant MTB RNAPs were expressed and 
purified. A plasmid-based, fluorescence-detected transcription assay (developed by Dr. 
Nathan Scharf) was used to characterize the potency of rifampin against both WT and 
RMPR mutant RNAPs.4 Results indicated that all RMPR mutations are highly effective at 
reducing RMP potency (see Figure II-6). The βH445Y RMPR was totally resistant to RMP, 
which was corroborated by structural work performed by Dr. Vadim Molodstov and Dr. 
Katsuhiko Murakami at Penn State University.5 The βH445Y (or βH526Y in E. coli) 
mutation induces conformational changes in the loops of the RRDR which causes a 
partial collapse of the RMP binding cleft (see Figure II-7C, Appendix Figure II-6). Their 
structural work also elucidated structural defects associated with the βS450L and βD435V 
mutants (βS531L and βD516V in E. coli). The βS450L mutant causes disorder in Fork 
loop 2 which results in solvent exposure to RMP, likely reducing its potency (see Figure 
II-7E, F).5 This in addition to steric induced clashes with leucine at the mutation position 
represent the structural basis for the reduced potency of RMP for the βS450L mutant. 
The βD435V mutation significant changes the electrostatic surface of the RRDR pocket, 
reducing RMP affinity. 
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RMPR mutants with secondary mutations which compensate for a fitness defect 
associated with the RMPR mutants were also investigated to determine the molecular 
basis for these fitness defects of the most prevalent RMPR mutants observed clinically.6-
8 Interestingly, the RMPR mutants have distinct mechanistic and kinetic profiles which may 
be interpreted to explain the prevalence of the mutations in clinical isolates.8-11 These 
studies provide a biochemical basis for the evolution of secondary, compensatory 
mutations observed in the β’-subunit of RNA polymerase (see Figure I-5). We conclude 
that the main contributing factor is maintaining a balance between RNAP elongation rate 
and termination efficiency. The significant defect in elongation rate seen for the βS450L 
mutation allows for increased termination efficiency; but likely contributes to the presence 
of compensatory mutations which mitigate the elongation rate defect. The defect in Fork 
loop 2 which was observed in the crystal structures discussed above seems to be the 
cause of the elongation rate defect in the βS450L (see Figure II-7E, F, Figure III-2). 
Additionally, both the RMPR and compensatory mutations lie on opposite sides of the 
DNA•RNA heteroduplex within the main channel and are likely affecting both elongation 
and termination by altering the efficiency of the clamp domain which normally stabilizes 
the RNA•DNA template heteroduplex on RNAP (see Figure III-5).12-13 Mutations in RRDR 
have been shown to effect RNA slippage, consistent with the heteroduplex•RNAP 
complex being de-stabilized by their presence.12, 14  This is also corroborated by our RNA 
primer hydrolysis data, which shows the β’V483G mutant, which is in the DPBB adjacent 
to the clamp, causes increased hydrolysis of RNA primer, likely by effecting the DNA•RNA 
heteroduplex complex stability on RNAP. 
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Another factor which seems to drive secondary mutations in the β’-subunit is their 
effect on the open-promoter complex (RPo) stability. All of the mutations are on the same 
amino acid chain that leads into Fork loop 2. It seems likely that this is contributing to RPo 
destabilization as Fork loop 2 lies at the downstream fork of the transcription bubble, 
potentially weakening stability of the RPo at this position.5  Further studies which probe 
the structural consequences of the RMPR mutant fitness defect compensation by 
compensatory mutations in the β’-subunit are needed to confirm how the secondary 
mutations are altering RNAP structure to elucidate the exact molecular mechanism of 
action of these mutations. 
RNAP is a validated antibacterial target; however, traditionally the focus has been 
on targeting transcription via direct inhibition of RNAP activity (see Figure I-7). There are 
several existing inhibitors which do not directly bind to RNAP. Bicyclomycin is an inhibitor 
of Rho dependent termination and there are several AraC-family inhibitors .15-19 AraC acts 
by recruiting RNAP to a promoter and has been proposed to stimulate RPo formation, 
though this is contentious as structural work supports a “recruitment only” mechanism 
through interactions with the C-terminal domain of the RNAP α-subunit.20-21 Therefore, 
regulation of the RNAP open-complex (RPo) formation appears to be an untapped target 
for novel antibacterial targets. CarD a transcriptional regulator in MTB which stabilizes 
the RPo through bipartite interactions with both RNAP and promoter DNA (see Figure I-
8, Figure III-1).22-23 CarD has been shown to be required for MTB viability and it 
represents a potentially novel therapeutic target.24-25  
A fluorescence polarization assay which probes the interaction between CarD and 
RPo was developed, optimized, and validated (see Figure IV-1-6). Due to the differential 
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affinity of CarD for free RNAP and the RPo, this assay can be used to not only inhibitors 
of CarD binding to RPo*DNA, but also DNA association with RNAP. This is evidenced by 
the observed inhibition of CarD FP by fidaxomicin which blocks DNA association 
preventing RNAP clamp closure and RPo formation (see Figure IV-5).26-27  
The CarD FP assay is optimal for HTS. The CarD•RPo FP signal is stable over 
hours and the assay is robust for HTS. Competition experiments with unlabeled CarD 
indicate that the fluorophore labeling does not affect CarD binding to RPo. In pilot screen 
of 237 small molecules demonstrated that this assay has an excellent z-score (0.77, see 
Figure IV-6), though no inhibitors were identified from this library. A larger library, MB24K 
(see Figure IV-7), which consists of 23,320 compounds selected by medicinal chemists, 
was screened. The assay had an excellent overall z-score (0.73, see Figure IV-7); 
however, there was significant spectral overlap between our fluorescent probe (BODIPY 
FL) and compounds in the library which lead to an unprocessed hit rate of 4.26%.  
Triage of compounds to remove fluorescence-interfering compounds using the 
parallel fluorescence intensity, as well as, those which were identified by NIH flags 
brought our hit rate from the primary screen down to 1.8% which is still higher than the 
anticipated 1% (see Figure IV-7B, 8). Though the hit rate was high we decided to move 
forward with this set and eliminate compounds during confirmation and in the counter 
screen. Roughly 50% of compounds tested during confirmation did not reconfirm bringing 
our hit rate down to 0.9% (see Appendix Figure IV-12A, B). Again, we had to eliminate 
several compounds because of potential interference issues and also PAIN compounds 
(see Figure IV-8). A counter screen was conducted to identify false positives due to CarD-
Bodipy interference and by the end of this process we were left with 109 out of 23,320 
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compounds or a 0.47% triaged hit rate (see Appendix Figure IV-12C). Of these, 100 
compounds were tested for concentration response (CRC) and we had 59 actives. We 
ordered 33 fresh powders for reconfirmation. 
Of the 33 powders we ordered, only 8 reconfirmed in our FP assay, and these are 
relatively weak inhibitors (see Table IV-1). However, protein-protein interactions are 
difficult to target because they usually have large and flat interfaces which are difficult for 
small molecules to bind with any significant affinity. Therefore, it seems fortunate to have 
found anything in this limited screen. MAS-16 appears to selectively bind to CarD (see 
Figure IV-9) in a direct binding SPR assay which is promising. Initial attempts at modeling 
MAS-16 in the CarD structure show that MAS-16 can bind in the region between the N-
terminal RNAP interacting domain and the C-terminal DNA binding domain. This potential 
binding mode is not yet confirmed; however, in addition to validating the model, this could 
serve as a preliminary model identify analogs of MAS-16 which may have increased 
potency. Several other biochemical assays should be performed on the remaining hits to 
determine whether they act by preventing RNAP association with promoter DNA, which 








In conclusion I have prepared several biochemical assays and their constituents 
which have allowed us to probe MTB RNAP mechanistically. We have strong biochemical 
evidence which explains the observed clinical prevalence of particular RMPR mutants and 
have provided strong evidence supporting a rationale for the evolution of fitness 
compensating mutations observed in RMPR MTB. I have also set the foundation for the 
discovery of novel inhibitors of the MTB transcriptional regulator CarD. This work is still 
in the initial discovery phase and will be the foundation for a campaign to try and identify 
more selective and potent inhibitors of CarD. 
 
Figure V-1: Model of MAS-16 docked into MTB CarD using MOE. A) Full length MTB 
CarD with MAS-16 virtually docked (PDB: 4KBM). B) Close up of 
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